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“Cancer is the ultimate nemesis that hangs in the balance for one in three women
and one in two men in their lifetime.”




Radiation therapy is an important component of cancer treatment. The fa-
vorable characteristics of proton radiation open the possibility of conforming the
treatment dose to the target volumes and sparing of the surrounding healthy tis-
sue. Pencil beam scanning is the current state of the art treatment method for
delivering proton therapy. Accurate delivery of the prescribed radiation dose in a
cancer patient, requires precisely calculated dose distributions. Commercial treat-
ment planning systems (TPS) must compromise in the level of accuracy in order
to compute the radiation plans in a reasonable amount of time. This trade-off
can be considerable, especially in heterogeneous regions or in the case of metallic
implants. Monte Carlo (MC) simulations are currently the gold standard in dose
calculation. The FLUKA MC Code is a general purpose MC tool that enables
recalculation of dose distributions and verification, in addition to more detailed
studies not feasible in a TPS or other more specific MC codes. All treatment plan
information is contained in a common format (DICOM), which must be adapted
to be readable for most MC tools, including FLUKA.
In this project, a tool that translates treatment plan information into data
readable for the FLUKA code was developed. The tool includes several routines
based on Python scripts. It enables reading of relevant treatment plan settings
required to automatically generate a FLUKA simulation file for dose recalculation.
Functions for data analysis and visualization, as well as comparison between the
TPS and FLUKA results were also created. In addition, scripts for converting
a FLUKA calculated dose distribution into DICOM format were created. The
results in this work demonstrate the feasibility of FLUKA MC recalculation of TPS
generated dose distributions through the developed software. Treatment plans
for both water phantoms and for actual patients were successfully recalculated
in FLUKA. The FLUKA doses were also exported to DICOM files and can be
imported back into a TPS for dose evaluation. The results further stress the
importance of detailed information and calibration to the specific beam line for
obtaining clinical precision of the recalculation process.
This developed and tested tool is a contribution to software that enables MC
treatment plan verification and can further be implemented in proton and particle
therapy TPSs. Furthermore, the tool enable detailed studies of the dose distribu-
tions, including linear energy transfer (LET) and secondary particle production.
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On a clinical level, cancer is not one disease, but rather a term referring to a large
number of diseases. However, in the end, cancer’s overall result is an imbalance
of cell replication and cell death. If these cells has the ability to invade locally,
spread to regional lymph nodes and to metastasize to distant sites in the body,
the cancer is characterized as malignant and may further be lethal. Cancer can
result in an expansion of cancerous tissue, known as a tumor [1].
Cells in the human body replicate and die every second. Cell replication is
what makes children grow, wounds heal and people age. When a cell replicates,
it transfers the genetic code of its DNA to the new cell. Normal healthy cells
become cancerous as a result of mutations caused by changes in the DNA. While
this occurs quite often, DNA enzymes repair most of these mutations. However,
the enzymes are not 100 % effective, and thus, cancer in the form of, for example,
a tumor can occur in all parts of the body. If the tumor is malignant it can be
highly dangerous, deadly, and difficult to remove [2].
According to the World Health Organization, cancer is the worldwide leading
cause of death for people under the age of 85 [3]. In 2013, a total of 29,793
Norwegians were diagnosed with cancer, whereas the same year, 10,699 people
died of the disease [4]. The number of cancer incidences will continue to rise
further, mainly due to the increase in population and life expectancy, as cancer is
strongly related to age [1]. This demands for more and better treatment methods.
In 2011, more than 11,000 patients were treated using radiation therapy with
photons in Norway [5]. Over half of all patients diagnosed with cancer will receive
radiation therapy, either as a standalone treatment, or in conjunction with other
treatment methods such as surgery and chemotherapy [6].
Radiation therapy using protons or heavy ions, also known as particle therapy,
is still limited compared to photon therapy. The use of particle therapy is however
expected to greatly increase in the years to come [7]. Since the first person was
treated in 1954 [8] at the Lawrence Berkeley Laboratory in California, by the year
2014, more than 137,000 patients has been treated by particle therapy worldwide,
where 86 % of the treatments were conducted with protons. By the end of 2014,
48 particle therapy facilities were in clinical operation, and in 2015, more than 30
particle therapy centers were under construction worldwide [9]. Norway received
its consent for the startup of particle therapy facility planning by the Minister
of Health and Care Services in 2013 [10]. The potential treatment centers are
currently still in the review process.
1
2 Chapter 1. Introduction
1.1 A Short Radiotherapeutic History
On November 30th, 1895, Wilhelm Röntgen announced his discovery of X-rays. At
the end of January 1896, approximately 60 days after Röntgen’s announcement,
Emil Grubbe, a second-year medical student treated the first two patients with
X-rays. The first was breast cancer and the other, skin lesions due to Tuberculosis.
This gave birth to radiation therapy [11].
Radiation therapy has been constantly developing for the last 120 years. How-
ever, the aim has always been the same, to deliver as close as possible to 100 % of
the prescribed dose to the target volume, while at the same time spare as much of
the healthy tissue as physically possible. The advancements since 1895 have been
tremendous.
In the beginning, treatments were available for only superficial tumors and
melanomas, due to the relatively low photon energies that were achievable. But
as the years went by, both supervoltage X-ray tubes and linear accelerators were
developed, which allowed for treatment of more deep-seated tumors. As early
as in 1906, different patterns of radiosensitivity were demonstrated, and in 1934
radiation dose deliverance using fractionation, as opposed to deliver all the dose at
the same time, was proposed. These developments, amongst others, led to better
cure rates for cancer and less damage to healthy tissue [3].
In 1953, the first linear accelerator for photon therapy was installed in London.
This was only a few years after Robert Wilson’s emphasis on the therapeutic
advantage of using protons in radiation therapy in his article Radiological Use of
Fast Protons [12] published in 1946. He also proposed the use of heavier ions.
As mentioned, the first patient was treated with protons as early as in 1954,
while treatments using helium- and neon ions were first conducted in 1957 and
1975, respectively [8]. In the years following the 1960s, the definitions of target
volumes and organs at risk were identified by the International Commission on
Radiation Units and Measurements (ICRU). The first treatment planning systems
also arrived, allowing more accurate treatment planning [3].
Thanks to Godfrey Hounsfield’s development of the CT scanner in 1971, ra-
diation planning started to shift from two- to three dimensions. In consequent
years, CT-based simulations and dose planning were introduced, and computer
driven multileaf collimators (MLC) conforming the radiation field, were developed
in the 1990s. With this, radiation therapy treatment could be done by sculpting
the dose in three dimensions onto target volumes and easier avoidance of organs
at risk could be accomplished.
Going into the early 2000s, intensity-modulated radiation therapy (IMRT)1,
followed by volumetric modulated arc therapy (VMAT)2 and adaptive radiation
1Intensity-modulated radiation therapy: Treatment using computer based algorithms to mod-
ulate the photon beam intensity by changing the MLC positions. Dose calculations performed
via inverse planning.
2Volumetric modulated arc therapy: Similar to IMRT, only that the gantry is continuously
moving during beam radiation. Effective for decreasing the treatment duration.
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therapy (ART)3 had a significant effect on the successfulness of radiation ther-
apy. The many delivery techniques and methods developed in the last century
have made it possible to personalize the radiation therapy techniques based on
different types of patients, tumor extents and locations. However, the spatial dose
distribution from photons must unfortunately follow the laws of physics, meaning
that there is an upper limit to the achievable dose conformity. Which brings us
to the usage of particles in radiation therapy [3, 13].
1.2 The Rationale and Motive for Particle Ther-
apy
One of the biggest advantages of conducting radiation therapy using protons or
heavy charged particles, like carbon- or helium ions, is the mechanics of their
dose deposition compared to photons [14, 15]. Photons have a short build-up
region, followed by an exponential decrease in the dose deposition with increasing
depth. This means that a considerable amount of healthy tissue will receive dose
for photon treatment of deep-seated tumors. And due to the penetrating ability
of photons, tissue beyond the target of interest will also be irradiated [16]. In
1946, Robert Wilson based his statements, about the advantage of using protons
in radiation therapy, on their well-known physics; they slow down during material
penetration. As the velocity of a proton decreases, the energy loss per unit length
increases, causing a maximum dose deposition at a certain depth. This region of
dose deposition is known as the Bragg peak, located near the end of the protons’
range. It is followed by a rapid decrease in dose deposition, and the protons
will not penetrate any further. The proton penetration depth is highly energy
dependent, and thus by adjusting the beam energy, the Bragg peak can be spread
out over e.g. a tumor, creating a so-called spread-out Bragg peak (SOBP) [7]. The
same applies to, for example, carbon ions. The main difference is the considerably
sharper carbon Bragg peak, in addition to the extended fragmentation tail located
after the peak [8].
The depth dose curves for photons, protons and carbon ions are shown in
Figure 1.1. The figure depicts the dose from a single field for all three particles.
For protons and carbon ions, there are some treatment cases where only one field
is used. On the other hand, there are also many cases where two or more beams
are applied to achieve an even higher dose conformity [18]. For photons, a single
beam is rarely used [19]. Following the development of IMRT and VMAT, a higher
dose conformity for photon therapy was achieved [3], meaning that it was possible
to distribute the dose over more tissue, reducing the amount of healthy tissue
receiving high doses compared to what Figure 1.1 shows. However, the external
modulations and conformations applied in photon therapy can also be used in
particle therapy, and due to heavy charged particles’ much more advantageous
physics, a lower integral dose, perhaps as high as a factor of 2-3 [20], may be
3Adaptive radiation therapy: Changing the radiation plan during the course of treatment to
account for anatomical changes such as tumor shrinkage, weight loss etc.
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Figure 1.1: The depth dose curves for photons, protons and carbon ions.
The protons and carbons deposit a large fraction of the dose deep into
the medium, while the photons have a maximum dose deposition a few
centimeters into the medium. The dashed red line shows a proton SOBP.
Also notice the sharper carbon Bragg peak, in addition to the fragmentation
tail [17].
achieved [21]. Two-dimensional dose distributions from radiation plans for photon-
and proton treatment are seen in Figure 1.2.
There are indications that patients undergoing radiation therapy may have an
increased risk of secondary malignancies as a result of out of out-of-field doses to
healthy tissues [23, 24]. There has in addition been shown a significantly higher
risk of developing radiation-induced cancer for pediatric patients treated with
photon treatment techniques as compared to proton therapy [25]. Considering that
the risk of developing radiation-induced cancer increases throughout a patient’s
lifetime [26], reducing the total dose can potentially increase the overall quality
of the life for pediatric patients. There are however discussions as to whether the
advantages of particle therapy are clinically significant for all treatment sites [7].
There are also concerns about the cost of proton therapy. An article [27], pub-
lished in 2010, estimated a cost ratio between particle therapy and photon therapy
to 4.8 for combined proton and carbon ion facilities, and 3.2 for proton-only fa-
cilities. The cost of particle therapy is however expected to decrease, and if it is
possible to reduce the risk of secondary malignancy by using particles in cancer
treatment, in addition to lower the number of treatment fractions, fewer people
will need treatment for side effects, and patients will spend less time in the hos-
pital. Therefore, particle therapy may be ultimately economically advantageous
compared to photon therapy.
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Figure 1.2: Dose distributions for a prostate cancer patient using VMAT
and intensity-modulated proton therapy (IMPT). Notice the increased out-
of-field doses to healthy tissues by VMAT [22].
1.3 Monte Carlo Simulations in Particle Ther-
apy
Due to the finite range of protons and ions and the steep distal dose fall-off, particle
therapy is a treatment modality capable of delivering high-precision and conformal
treatments. However, a safe and optimal treatment relies on a good correspon-
dence between the planned and delivered dose to the patient [28]. Heterogeneities
in tissues are of a much higher importance in proton therapy compared to conven-
tional photon therapy. The range of protons is strongly dependent on the density
of the tissues they traverse, and as a result, the distal part of the dose distribution
can be substantially affected by heterogeneities [29, 30].
There are three main models for dose calculation in proton therapy; uniform
intensity beam algorithms, pencil beam (PB) algorithms and Monte Carlo cal-
culations [31]. A necessity for all three is that they require an accurate three-
dimensional description of the patient anatomy in the form of computed tomog-
raphy images. The uniform intensity beam algorithms are the least accurate and
will not be discussed further.
Commercial treatment planning systems (TPS) are today used by clinics in or-
der to calculate radiation plans for patients. TPSs usually rely on PB algorithms
to calculate the dose, which are considered to offer a reasonable compromise be-
tween accuracy and computation time. This method models the incident beam
using closely spaced finite PBs, each assigned its own weight directly proportional
to the particle fluence for the respective beam. Measured or calculated data is
used for modeling the spread of the PB due to multiple Coulomb scattering, in
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addition to the depth dose distribution. The total dose in any point can then
be computed by summarizing the contributions from each PB [31]. Although PB
algorithms are highly accurate, they can still encounter problems for dose calcula-
tions in low-dose regions, in very heterogeneous tissues or if metallic implants are
present. This is where Monte Carlo calculations are most desirable due to their
superior accuracy [15, 32–37].
Monte Carlo simulations are considered the gold standard for dose calcula-
tions in particle therapy [38, 39]. The reason for the high accuracy is that the
physics of interactions for each and every particle is taken into account using
theoretical models or experimental data for electromagnetic and nuclear interac-
tions. They further consider material specific properties, as for example elemental
composition, electron density, ionization potential, and so forth [35]. In addition,
secondary particles can be tracked, which allow for nuclear fragments to be stud-
ied. However, the accuracy of the dose calculations performed depends on the
calculation duration. As a result, in order to obtain sufficient statistical accuracy,
a substantial amount of particles must be tracked. These calculations can require
a lot of time, making them potentially unsuitable for clinical applications on a rou-
tine basis. But Monte Carlo simulations are regularly used for TPS benchmarking,
in addition to being the preferred choice for special geometries, e.g. metallic im-
plant cases. Monte Carlo simulations are, in addition, often used for recalculation
or validation of analytically calculated dose distributions, and for to treatment
plan optimization. And as time moves forward and the computational efficiency
increases, the Monte Carlo code will hopefully become optimized for routine clin-
ical use and may replace the pencil beam algorithms as the standard method for
patient dose calculation [16, 31].
1.4 Project Objectives
The main objectives of this project has been to:
 Develop and test a procedure to extract CT-scans along with proton ther-
apy treatment plans from commercial dose planning systems, and further
translate and import this information into the FLUKA [40, 41] Monte Carlo
tool to enable dose recalculation and validation of treatment plans.
 Develop tools for versatile comparisons of the initial- and recalculated dose
distributions, in addition to making studies of biologically relevant parame-
ters such as linear energy transfer distributions feasible.
Chapter 2 provides the basic physics relevant for particle therapy. This in-
cludes the main interactions of heavy charged particles, alongside a short summary
of basic dosimetry and radiobiology focusing on linear energy transfer and relative
biological effectiveness.
Chapter 3 emphasizes the main aspects of the particle therapy processes.
Treatment planning, followed by plan assessment, treatment delivery and uncer-
tainties in particle therapy are successively discussed. A short introduction to the
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DICOM file standard and the coordinate systems involved in the project is also
found in this chapter.
Chapter 4 contains the method of developing and applying the scripts in this
project. The most important aspects to consider when developing this tool are
outlined.
Chapter 5 presents the results obtained when testing the developed tool.
Two-dimensional dose distributions from commercial treatment planning systems
alongside FLUKA recalculations, in addition to one-dimensional dose curves and
dose volume histograms are shown.
Chapter 6 contains the discussion, outlined shortcomings, potential for the
tool and suggestions for further work.
Chapter 7 forms the final conclusion.




Physics of Particle Therapy
2.1 Charged Particle Interactions in Matter
2.1.1 Energy loss by ionization and excitation
Heavy charged particles, i.e. particles with mass greater than the electron rest
mass, lose energy while traversing through matter mainly by collisions with bound
electrons. In these collisions an electron can either be raised to a higher shell in the
absorbing atom (excitation) or it can be ejected from the atom (ionization). If the
ejected electron receives enough kinetic energy, it can cause further ionizations.
These electrons are referred to as δ-electrons [42]. The energy loss per collision is
typically very small. However, because of the high number of collisions per unit
path length, a substantial fraction of the interacting particle’s kinetic energy can
be transferred to a relatively thin layer of matter [43]. The mean energy loss per





























2 ≈ 0.307 MeVcm2g−1 ,
and Wmax is the maximum energy that can be transferred to a free electron in a












Table 2.1 provides the variables used in the Bethe-Bloch equation. The mean
excitation potential, I, is in essence Planck’s constant, h, times the electrons
average orbital frequency, ν̄ [43]. Using a correctly determined excitation potential
is of high importance in particle therapy as the uncertainty of the excitation
potential for tissues can be as high as between 5 − 15 % [30] and can alter the
calculated energy loss, and thereby the beam range by as much as 1.5 % [21].
The shell correction, C, is important at low energies, i.e. when the velocity of
the incoming particle approaches and becomes smaller than the orbital velocity of
the electrons in the absorbing material. The correction is applied in the energy
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Table 2.1: Relevant parameters used in the Bethe-Bloch equation.
Symbol Definition Value and/or unit
ρ Density of material g cm−3
Z Atomic number of material
A Atomic mass of material g mol−1
z Charge number of incident particle
β v/c of incident particle
me Electron mass MeV c
−1
m Mass of incident particle MeV c−1
c Speed of light in vacuum 2.998× 108 m s−1
γ Lorentz factor 1/
√
1 − β2
I Mean excitation potential eV
δ(βγ) Density effect correction
C Shell correction
NA Avogadro’s number 6.022× 1023 mol−1
re Classical electron radius 2.818 fm
v Speed of incident particle m s−1
Wmax Maximum energy transfer in a single collision
range of 1−100 MeV, and the maximum correction is about 6 % [45]. The δ-term,
i.e. the density correction, is only relevant for proton energies higher than for
therapeutic purposes [45, 46].
The energy loss for a heavy charged particle is highly energy dependent and is
therefore mostly determined by the particle’s velocity. For non-relativistic particle
energies, the first term in equation (2.1) is predominant, and thus the energy loss
has a 1/β2 dependence. For even lower energies, about 10 MeV or less [42], the
Bethe-Bloch equation is no longer valid, and phenomenological fitting formulas
and other theories are used to describe the energy loss [44]. The stopping power
for protons with energies of ∼ 0− 200 MeV traversing through water is shown in
Figure 2.1.
2.1.2 Multiple Coulomb scattering
A charged particle traversing through an absorber will not follow a straight path.
The particle will be elastically scattered in many small angles [44]. This scattering
is mainly due to the incident particle’s electric charge interacting via the Coulomb
force, i.e. deflection in electric potential of nuclei. This will lead to broadening
of particle beams used in radiation therapy [42]. The lateral deflection is smaller
for particles heavier than protons and is proportional to the charge of the incom-
ing particle and inversely proportional to the projectile’s velocity and the atomic
weight [17]. Consideration of the lateral spreading is highly important in particle
therapy as the amount of spread is also dependent on the beam line, the distance
between the treatment nozzle and the patient, and other treatment room specifics
[42]. The lateral spread of protons and carbon ions is illustrated in Figure 2.2.
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Figure 2.1: Stopping power for protons (∼ 0−200 MeV) in water. The data
is provided by the National Institute of Standards and Technology
(NIST) [47].
Figure 2.2: Lateral spread for proton- and carbon beams as a function of
depth in water. The protons have a three times larger broadening than the
carbon ions for the lowest energies depicted on the left. The dose tail, as a
result of fragmentation of the carbon ions, can also be seen [17].
2.1.3 Nuclear interaction and fragmentation
Nuclear interactions are, in addition to excitation and ionization, the primary in-
teractions of charged particles in the energy range used in particle therapy [42].
The incoming particles can interact with the nucleus by knocking out secondary
particles like protons, neutrons, and light ion clusters. These knocked out particles
have, in most cases, a considerably lower energy than the initial particle [7]. How-
ever, in all radiation therapy, secondary particles contribute to the total absorbed
dose and if a secondary particle is neutral, it is not affected by the Coulomb force
and may travel longer, leading to dose deposition outside the target volume [48].
As a result of the beam fragments’ forward momentum due to the high velocity
of the primary beam particles, an additional dose will be deposited beyond the
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maximum range of the primary particles [17]. This effect, see Figure 2.2, is more
prominent for carbon ions than protons, considering that the former are composite
particles.
2.1.4 Energy-range relation for charged particles
Obtaining the range of a charged particle in matter can be a complicated task as
fluctuations in the energy loss, multiple Coulomb scattering and collisions with
high energy transfers can lead to considerable energy straggling. From a theoret-
ical point of view, the mean range of a given particle can be calculated by the
Continuous Slowing Down Approximation (CSDA), where the stopping power,









The range for protons of energy 0− 200 MeV is shown in Figure 2.3.



















Figure 2.3: The CSDA range vs. energy for protons (0−200 MeV) in water.
The data is acquired from Libamtrack [50].
2.1.5 The Bragg peak
A charged particle continuously loses small fractions of energy when traversing
matter. This energy loss causes the particle to slow down and the rate of inter-
actions per unit length increases, leading to a maximum energy loss at the end of
the particle’s range. This region of maximum energy loss is called the Bragg peak.
Ideally the energy loss just after the Bragg peak should drop rapidly to zero. As
this is the case for a single particle, due to statistical fluctuations in the energy
loss, a monoenergetic beam will show the effect of range straggling. This can be
seen as a small tail at the end of the particles’ range [7]. The Bragg curve for
200 MeV protons in water is shown in Figure 2.4.
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Figure 2.4: FLUKA [40, 41] Monte Carlo simulation of the Bragg curve
for 200 MeV protons in water. Notice the Bragg peak at the end of the
trajectory.
2.2 Dosimetry
The amount of damage in tissue due to ionizing radiation must be measured with
a unit suitable for both radiation protection and radiation therapy [51]. The
accuracy of the determination of absorbed dose is highly important, as a small
offset of the tumor dose may be the difference between underdosage, thereby
failing to control the tumor, and overdosage, potentially resulting in noticeable
damage to healthy tissue [7].
2.2.1 Absorbed dose
Radiation damage depends on the amount of energy departed by radiation. It is
proportional to the mean concentration of absorbed energy in the irradiated tissue.
ICRU defines absorbed dose as the mean energy imparted by ionizing radiation,





The unit for absorbed dose is called Gray (Gy) in the SI system, where 1 Gy =
1 J
kg
. An important thing to remember is that the energy lost by e.g. a proton
beam is larger than the absorbed dose. This is because a part of the beam’s energy
will be transformed into neutral secondary particles, e.g. photons and neutrons,
which may deposit their energy outside the volume in question [7].
2.2.2 Equivalent dose
Different kinds of radiation have a different biological effect on tissues. In terms
of dose, this difference was introduced in 1977 as the equivalent dose [53]. A
weighting factor, wR, was suggested to differentiate between different particles
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where wR is the weighting factor for distinct radiations, tabulated in Table 2.2,
and DT,R is the absorbed dose averaged over the irradiated tissue(s). The unit for
equivalent dose is Sievert (Sv) defined as 1 Sv = 1 J
kg
[54].
Table 2.2: Radiation weighting factors as defined by the International Com-
mission on Radiological Protection (ICRP) in ICRP Publication 103 [55].
Radiation type Weighting factor, wR
Photons 1
Electrons and muons 1
Protons and charged pions 2
Alpha particles, fission frag-
ments and heavy ions 20
Neutrons:
En < 1 MeV 2.5 + 18.2e
−[ln(En)]2/6
1 MeV ≤ En ≤ 50 MeV 5.0 + 17.0e−[ln(2En)]2/6
En > 50 MeV 2.5 + 3.25e
−[ln(0.04En)]2/6
2.2.3 Effective dose
The equivalent dose is not concerned as to which tissues are being irradiated.
Therefore, ICRP has introduced the effective dose where tissue dependent weight-








where wT is the tissue weighting factor, tabulated in Table 2.3. The unit for ef-
fective dose is also Sv [55].
Table 2.3: Tissue weighting factors as defined in ICRP Publication 103 [55].
Organ/tissue Weighting factor, wT
Breast, bone marrow, colon, lung,
stomach, remaining tissues* 0.12
Gonads 0.08
Bladder, liver, esophagus, thyroid 0.04
Bone surface, brain, salivary glands, skin 0.01
*Adrenals, extrathoracic region, gall bladder, heart, kidneys, lymphatic nodes, muscle, oral
mucosa, pancreas, prostate, small intestine, spleen, thymus, uterus/cervix.
Chapter 2. Physics of Particle Therapy 15
2.3 Radiobiology
Radiobiology, the branch of science that deals with the effects of ionizing radiation
on living systems, is a combination of the basic principles of physics and biology. In
radiation therapy, the main goal is to kill the cancer cells. Death for proliferating
cells is defined as the loss of reproductive integrity, also called reproductive death
[56]. The most radiosensitive part of a cell is the DNA molecule [57]. If the DNA






















Figure 2.5: Illustration of direct- and indirect single-strand break DNA
damage caused by ionizing radiation. Modified from [57].
Different kinds of radiation interact with the DNA molecules in different ways.
When a photon is absorbed in the cell, free electrons (δ-electrons) are produced.
For radiotherapeutic energies, this happens mainly through the Compton process
[56]. These δ-electrons may further ionize atoms in the medium and are able
to split one or two of the DNA strands if they are close enough. This type of
interaction is called direct action and will in most cases lead to double-strand
break (DSB). However, in photon therapy, the majority of strand breaks, i.e.
about 70 %, are caused by the so-called indirect action [59]. In indirect action,
the produced δ-electrons do not hit the DNA itself, but rather interact with water
in the cells. These interactions produce a free radical, OH, which further has the
ability to damage the DNA (see Figure 2.5). The disadvantage of indirect action is
that more often than not, the damage to the DNA occurs by single-strand breaks
(SSB), which is easier to repair than DSBs [57].
2.3.1 Linear energy transfer
Protons and heavier ions have a higher ionization density compared to photons, at
least for low energies [56]. As a result, more δ-electrons are produced resulting in
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an increased probability to perform DSBs, and thus, more efficient cell inactivation
can be achieved with therapy using protons or heavier ions.
Linear energy transfer (LET) is used in radiobiology as a measure of the quality
of the ionizing radiation. The International Commission on Radiation Units &
Measurements (ICRU) defines the LET as follows [52]:
The linear energy transfer or restricted linear electronic stopping power,
LET∆, of a material, for charged particles of a given type and energy,
is the quotient of dE∆ by dl, where dE∆ is the mean energy lost by the
charged particles due to electronic interactions in traversing a distance
dl, minus the mean sum of the kinetic energies in excess of ∆ of all





The unit used for LET is typically keV µm−1, and the LET therefore represents
the local ionization density in a cellular state. Higher LET means more effective
cell killing per unit dose and vice versa for low LET. The demarcation between
low- and high LET is about 10 keV µm−1, and typical values are 2 keV µm−1 for
250 kVp photons. For heavy charged particles, the LET increases drastically for
lower energies (see Figure 2.6) which means that the charged particles are most
lethal at the distal end of the Bragg curve. Typical LET values for heavy charged
particles are about 100−200 keV µm−1 in the Bragg peak [19].















Figure 2.6: Linear energy transfer for 0−200 MeV protons in water. The
LET data is acquired from Libamtrack [50].
2.3.2 Relative biological effectiveness
The relative biological effectiveness (RBE) is a measure of the biological effect of a
certain kind of radiation. It is defined as the ratio between the dose of a reference
radiation and the dose of the given radiation to achieve the same biological effect.
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Historically, the reference radiation has been regarded as 250 kV X-rays. This was
done for clinical consistency and to benefit from a large amount of clinical results





Typically, all treatments in proton therapy assume an RBE of 1.1, a value which
is primarily based on animal experiments conducted in the 1970s [61]. However,
the RBE varies depending on a particle’s energy, depth of penetration, dose per
fraction and other parameters [7]. The single value of 1.1 is therefore only a generic
value. It has been shown in in vivo and in vitro studies that the RBE can vary
significantly [62], but there is no clear clinical data that indicates that the usage
of 1.1 as the generic RBE value is unreasonable [63]. On the other hand, there is
neither clear clinical data that confirms that an RBE of 1.1 is correct [7].
The RBE is closely related to the LET in the sense that the former increases
as the latter increases. At an LET of approximately 100 keVµm−1, the maximum
RBE is about 3-8, depending on the level of cell kill. Beyond this LET value, the
RBE declines due to cell overkill. This is because high LET particles are densely
ionizing and will deposit more energy to the DNA than what is required to kill
the cell, thereby decreasing the effectiveness. This effect is shown in Figure 2.7.
Figure 2.7: Illustration of the relationship between RBE and the mean LET.
Notice that the RBE is relatively constant around 1 for low-LET particles
as, for example, protons. SF is an abbreviation for survival fraction [54].

Chapter 3
Treatment Planning and Delivery
The aim of radiation therapy is to deliver the highest possible dose to the tumor
while at the same time sparing healthy tissue. In order to do so, a well-planned
treatment must be diligently chosen. In addition to the planning, plan evaluation,
deliverance and quality assurance are highly important, even more so in radiation
therapy with protons than photons, because of the protons’ high dose conformity
and tissue density dependence [31].
The impact of radiation on tumors and normal tissues can be measured by
evaluating the tumor control probability (TCP) and the normal tissue compli-
cation probability (NTCP). The TCP and the NTCP are dose-response curves
that depend on the dose delivered to the tumor and dose received by normal tis-
sues, respectively. By plotting the dose-response curves, their relative position
and shape can determine the possibility of delivering a sufficient amount of dose
with an acceptable level of side effects. The distance between the two curves is
called the “therapeutic window”, and an important part of the development of
radiation therapy is to be able to increase the size of this window [6]. Ideally,
delivering zero dose to the healthy tissue while at the same time delivering all the
dose to the tumor is the desirable situation [17]. However, this is not possible, and
the compromise between the NTCP and TCP will always be an issue in radiation
therapy.
Figure 3.1: The therapeutic window separating the NTCP curve (red) from
the TCP curve (black). Wider windows are preferable [17].
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3.1 Treatment Planning
3.1.1 Image acquisition
During treatment planning for a cancer patient, precise quality images of the
patient are required for assessing the extent and position of the tumor and possible
organs at risk. Images are also needed to obtain tissue density information for
accurate dose distribution calculations, and for precise patient setup.
The most common medical imaging modalities are computed tomography (CT),
positron emission tomography (PET), magnetic resonance imaging (MRI), and ul-
trasound (US). While all four modalities have their advantages and disadvantages,
CT is the gold standard in radiation therapy due to its ability to acquire tissue
density information [64].
Computed tomography (CT)
CT utilizes X-ray photons (energy of 20− 100 keV) to create an anatomical image
of the patient via X-ray attenuation.
Helical scanning, introduced at the end of the 1980s, revolutionized clinical
imaging. By continuously scanning the patient, image acquisition duration could
be drastically reduced, and thus, more accurate images could be acquired as a
result of less motion artefacts. In helical scanning, the X-ray tube, emitting pho-
tons, rotates around the patient with one revolution taking less than a second. At
the same time, the patient is moved through the gantry. The level of photon at-
tenuation in the patient will depend on the material composition and the density
of the area of penetration. The intensity of the transmitted photons is measured
and counted by a bank of solid state detectors opposite the X-ray tube. By using
a computer, the helical information can be translated to slice-by-slice information,
i.e. data matrices of typically 512× 512 or 1024× 1024 pixels for each slice with
a thickness of a few millimeters [64, 65].




where I0 and I are the initial- and measured photon intensity, respectively, x is the
thickness of the matter in question and µ is the linear attenuation coefficient which
expresses the amount of photons absorbed per cm. If the initial intensity is known,
and the intensity of the photons that have penetrated the patient is measured, the
attenuation coefficient can be obtained. The coefficient is highly dependent on the
density of the traversed tissue. And so, by measuring the reduction in intensity,
density information can be translated into a gray scale image. The darker the
region of the image, the less attenuation has occurred, while the brighter regions
represent tissues/organs having a relatively high density [64] (see Figure 3.2).
The Hounsfield units
In order to easily compare images obtained from different CT scanners, Godfrey
Hounsfield introduced the Hounsfield units (HU), also referred to as CT numbers.
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Figure 3.2: CT image of a prostate cancer patient acquired at Haukeland
University Hospital. The white dots in the middle, lighting up in the image
due to their very high density, are gold markers used for patient positioning.
The measured Hounsfield unit for the markers was around 3000.
The HU scale is expressed relative to the linear attenuation coefficient of water
which was assigned a Hounsfield unit of 0. He also assigned HU = 1000 to dense




× 1000 . (3.2)
The Hounsfield units are directly related to the attenuation coefficient as a
change of 1 HU equals a difference of 0.1 % between the attenuation coefficient
of the tissue and the attenuation coefficient of water [65]. In proton therapy
the HUs are further converted into relative stopping power values (relative to
water) for proton range calculations. However, as uncertainties in HUs are linearly
transferable to uncertainties in proton range calculations, an accurate conversion is
highly important in proton therapy [7, 66] and will be further discussed in section
3.4.
The calibration curve
The density information, and thus the relative stopping power for particle therapy,
is imported into the treatment planning system using a calibration curve (see Fig-
ure 3.3). The relationship between the Hounsfield units and the density/stopping
power is typically acquired by calibration of the CT scanner using a phantom with
substitute materials of known elemental composition [66]. The stopping powers
can be determined by using a simplified version of the Bethe-Bloch equation [67]
and may also be confirmed by direct measurements in proton beams [7].
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Figure 3.3: A typical HU to relative stopping power calibration curve used
in proton therapy [68].
3.1.2 Anatomical volumes and target delineation
By acquiring an anatomical image of a patient, volumes of interest such as tumors
and critical organs can be located and delineated. These are needed for prescrip-
tion, recording, and delivery of the treatment plan. In ICRU Report 50 [69],
targets and volumes used in radiation therapy are defined. Most of the volumes
have the same definitions for both proton- and photon therapy. The exception
is volumes that has specific treatment modality margins. These are specifically
described in ICRU Report 78 [31] for proton therapy.
Prior to treatment planning, the two volumes that should be defined are the
gross tumor volume (GTV) and the clinical target volume (CTV). Further volumes
to be defined and delineated during treatment planning are the planning target
volume (PTV) and the organs at risk (OAR). The anatomic regions of interest
(ROI) are delineated by a radiation oncologist slice by slice, and while it is a
time-consuming process, it is one of the most important ones [70].
Gross tumor volume (GTV)
ICRU defines the GTV as the gross palpable or visible/demonstrable extent and
location of malignant growth [69]. The GTV typically consists of the primary
tumor and other local metastases. The tumor cell density is always high in the
GTV and therefore an adequate dose must always be delivered to the whole volume
for radical therapy (curative treatment). The GTV’s extent, shape, size, and
location are determined by different means of diagnostic methods. This can be
imaging using CT, MRI, PET, etc. and/or by clinical examination, for example,
palpation, endoscopy and so forth. Depending on what method is used for GTV
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determination, the GTV can be quite different in size and shape. It is therefore
important to indicate the determination method used.
Clinical target volume (CTV)
Even though the whole macroscopic tumor has been delineated, surrounding tis-
sue close to the GTV typically contains subclinical malignancy in the form of
individual malignant cells, small cell clusters, or micro-extensions that can not be
clinically detected. In ICRU Report 50 [69], the CTV is defined as a tissue vol-
ume that contains a demonstrable GTV and/or subclinical microscopic malignant
disease which has to be eliminated. This volume thus has to be treated adequately
in order to achieve the aim of therapy, cure or palliation. The CTV delineation is
based on available data on the probability that malignant cells are located outside
the GTV and on individual judgment by the radiation oncologist. The CTV, in
addition to the GTV, are purely clinical-anatomical concepts, meaning that they
are defined without regard to movement of the tissues and/or patient.
Planning target volume (PTV)
Variations in beam sizes and directions, in size and shape of tissues containing
the CTV, movement of the CTV due to e.g. respiration, in addition to potential
patient setup errors, calls for an additional margin to the CTV. By adding this
margin, a new volume is defined by ICRU [31]: The planning target volume is a
geometrical concept, and it is defined to select appropriate beam sizes and beam
arrangements, taking into consideration the net effect of all the possible geometrical
variations, in order to ensure that the prescribed dose is actually absorbed in the
CTV. By adding an extra margin to the CTV, significant deviations from the
prescribed dose in any part of the CTV are kept to a minimum. In proton therapy,
beams can be designated directly to the CTV, taking into account the margins
within the aperture design, without referencing the PTV. However, a PTV must
always be defined due to the requirement of reporting purposes, and as a result,
each CTV will always have a corresponding PTV.
Organ at risk (OAR) and planning organ at risk volume (PRV)
When creating a radiation plan for a patient, normal tissues and organs that have
such a high sensitivity to radiation that they can significantly influence the treat-
ment planning and/or the prescribed dose, should be delineated. These volumes
are called organs at risk (OAR). Similarly as for the PTV, an additional margin
is added to the OAR in order to ensure that adequate sparing of the OAR is
achieved with a high probability. This leads to the concept of the planning organ
at risk volume (PRV). It is designed to help treatment planning and evaluation.
The uncertainties that need to be taken into account for the PRV are the move-
ment of the OAR during treatment, variation in patient positioning, mechanical
uncertainty of equipment, transfer setup errors from CT to the treatment unit,
and human factors [31, 69].
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(a) Illustration of the volumes and margins
related to the definition of the target
volume.
(b) Illustration of the volumes and margins
related to the definition of organs at risk.
Figure 3.4: Volumes and margins in proton therapy
as defined in ICRU Report 78 [31].
3.1.3 Dose planning
After anatomical images have been acquired, and target and organs at risk have
been delineated, the task of finding an appropriate treatment plan for the patient
can start. The CT images which are a virtual representation of the patient can be
imported, together with the outlined volumes, into the treatment planning system
available for the clinic. Typically, a radiation oncologist prescribes planning aims,
i.e. dose requirements and normal tissue constraints to the target volume(s) and
OARs, respectively. These planning aims are based on detailed evaluation of the
patient, diagnostic studies and other oncological concepts. The treatment planner
uses the planning aims as a basis for finding an acceptable compromise between
the dose to the target(s) and the OARs [7].
The preferable method of dose planning in particle therapy is the so-called
inverse planning. The treatment planner can specify the number of beams, where
each beam is defined by its specific parameters such as modality, field weight,
beam angle and so forth. The treatment plan can then further be simulated in the
TPS. Numerous simulations are conducted, where a computer algorithm evaluates
which plan fulfills the treatment prescription to a maximum extent [31], by for
example analyzing the therapeutic window, or by other methods. This is referred
to as plan optimization. The optimized plan must, in the end, be evaluated. The
optimization- and evaluation processes are further discussed below.
In treatment planning, it is always important for the planner to know the
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limitation of the TPS. The analytical dose calculation algorithms utilize certain
approximations which may lead to shortcomings in the accuracy of the calculated
dose [7]. Most semi-empirical dose calculation algorithms in use are different
variations of the pencil beam (PB) algorithm developed by Hong et al. [14]. The
dose distribution from a PB with a given energy is represented by the product of
a lateral profile term and a PB central axis depth dose term, obtained through
measurements of broad beam data in water. The dose at any point in the patient
is calculated by summing the dose contribution from all the PBs surrounding
the point of interest. The lateral spread of the pencil beams is assumed to be
describable by a function with Gaussian characteristics [70, 71].
3.1.4 Treatment plan optimization
The method of inverse planning is typically used for intensity-modulated particle
therapy (IMPT). IMPT in pencil beam scanning means that the scanning magnets
can steer the pencil beam and conform the dose in the transverse plane (see section
3.3.3). Dose conformation in this plane is also achievable for photons by IMRT
or VMAT. However, due to the Bragg peak of protons, an additional degree of
freedom is introduced, meaning that modulation along the beam axis is possible.
In IMPT, each pencil beam must be weighted relative to each other and must be
optimized separately [31]. The optimization process is an important part of the
treatment planning. Optimization is essentially to iteratively generate, followed
by automatically assessing, a large number of plans and choosing the best among
them. A computer is given constraints and objectives on targets and organs at
risk by a clinician. If given constraints, the computer must follow these without
violation. Objectives, on the other hand, are typically given weights relative to
each other, in which case a small violation may be allowed. An example of ob-
jectives can typically be 60 Gy to 98 % of the tumor volume, while no more than
20 Gy should be received by 30 % of a nearby OAR. When the computer have
calculated the best plan for the given constraints, it should be inspected by the
treatment planner. If the results are unsatisfactory, the objectives and constraints
can be edited and a new optimization process may be initiated [31].
Biological optimization
As written in chapter 2, treatments in proton therapy usually assumes a constant
RBE of 1.1. This means that converting the physical to biological dose is done
by multiplying the former with the RBE. Consequently, the optimization can be
performed based on the physical dose alone. However, as the RBE is closely
related to the LET, which increases at the distal end of the Bragg curve, there are
indications that the use of a constant RBE may not be the best approach [62].
Therefore a shift from optimization based on physical dose, to optimization
based on physical dose and LET to account for a variable RBE may be a better
method [7]. One approach to biological optimization has been suggested by J.
Wilkens and U. Oelfke [72].
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3.2 Plan Assessment
A treatment plan is evaluated by several different methods. Usually, dosimetrics
and volumetrics are inspected using dose distributions displayed onto patient CT
scans, and graphically using dose volume histograms alongside predetermined dose
constraints to target volumes and organs at risk [31].
3.2.1 Dose distributions
Two methods of displaying the dose distribution are either via two-dimensional
isodose curves or by a color wash overlaid on the three-dimensional CT images.
The color wash display of the dose gives the most qualitative representation of the
dose distribution. The dose distribution can typically be displayed in any two-
dimensional plane, with the transverse, sagittal or coronal plane being the most
common ones. In order for the dose distribution to be a good representation, a
well-defined color bar should be used, where typically cooler colors (purple, blue)
depicts lower dose, and warmer colors (yellow, orange, red) means higher dose. As
there is no satisfactory way to evaluate the dose distribution in three dimensions
in a single view, often, simultaneous displays of the dose distribution in different
planes are used [31, 73].
While the display of the dose transposed over the CT images gives a fast
impression of how the dose is distributed, it can be quite difficult to properly
evaluate treatment plans in terms of the amount of dose organs and targets receive.
Dose distribution display may also not be ideal for comparison purposes.
3.2.2 Dose volume histograms
Dose volume histograms (DVH) are a simple way to evaluate the dose distribution
on volumes of interest. Cumulative DVHs, showing the amount of dose up to a
given value received by a fraction of the total volume, are the most common type of
dose volume histograms. The DVHs can employ both relative and absolute doses
and volumes. By using DVHs for plan assessment and comparison, the spatial
information is lost. This loss of spatial information can, however, be compensated
for by using dose distribution displays in conjunction with the DVHs [31, 73].
3.3 Treatment Delivery
3.3.1 Accelerators in particle therapy
In order to use protons for therapeutic purposes, they first need to be accelerated
up to the desired energy, a task that is done by particle accelerators. In particle
therapy, the two main types of accelerators are the cyclotron and the synchrotron.
For protons, an energy of typically about 230−250 MeV is needed for a radiation
depth of 30 cm in tissue [13]. This can be achieved using both mentioned acceler-
ators. However, for heavier ions, their high magnetic rigidity can be a problem for
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cyclotrons. Therefore, with today’s technology, synchrotrons are the accelerators
used for particles heavier than protons.
The big advantage of cyclotrons, compared to synchrotrons, is that they can
provide a continuous particle beam. Cyclotrons can however only accelerate par-
ticles to a fixed energy, and thus a degrader must be used to vary the beam energy
in order to create a SOBP. Protons coupled with two electrons are accelerated
to therapeutic energies by an applied radio frequency wave inside the cyclotron.
The trajectories are further bent by a strong magnetic coil making the particles
travel in spiral shaped paths with increasing radius. When the particles reach the
desired energies, the electrons are removed and the protons are extracted from the
cyclotron. They can then be used for particle therapy [7].
For acceleration to therapeutic energies of heavier particles than protons, a
cyclotron will not suffice. A much larger accelerator, the synchrotron, is needed.
One or more linear accelerators are necessary for particle pre-acceleration before
entering the synchrotron. The synchrotron can provide very high particle energies
by having a large radius, and by increasing the strength of its magnetic bend-
ing fields. Unlike for the cyclotron, the energy the particles accelerated in the
synchrotron can be adjusted within the accelerator itself [7].
3.3.2 Energy modulation
A monoenergetic beam from the accelerator is unsuitable for cancer treatment
due to its longitudinally narrow Bragg peak. In order to cover the target volume
in its full depth, beams of decreasing energy, and typically decreasing weight, are
combined to create the spread-out Bragg peak (see Figure 1.1). This modulation
can be done either actively or passively [7].
Active modulation
Active modulation is only possible for synchrotrons. The energy of the beam
is changed directly within the accelerator and the energy change must happen
quickly in order to limit the treatment duration and to allow for fast switching
between treatment rooms. The energy selection must also be accurate in order to
determine the depth of the Bragg peak with sufficient accuracy [7].
Passive modulation
For cyclotrons, only passive modulation is available. This is because these accel-
erators only work at a specific energy. Passive modulation is achieved by inserting
material in front of the beam, thereby decreasing the effective energy, and thus
the range of the particles. This can either be done immediately after the beam
has been extracted from the cyclotron, or the modulation can take place directly
inside the treatment nozzle [7].
To create the SOBP, either a plate with ripples (ridge filter) or a rotating wheel
with varying thickness in the azimuthal direction (modulator wheel) is used. The
modulators are designed such that the result is a predefined depth dose profile.
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The SOBP can, in addition, be adjusted in depth by using an additional range
shifter consisting a number of plastic plates with varying thickness [73].
3.3.3 Beam delivery techniques
In addition to spreading the dose over the target in the longitudinal direction, the
dose must also be spread laterally. This can be done by different beam delivery
techniques. The two major delivery techniques in particle therapy are referred
to as active beam shaping (beam scanning) and passive beam shaping (beam
scattering) [74].
Passive scattering
Passive scattering was the first method to be developed. In this delivery technique,
the narrow particle beam is spread in the lateral direction either by using one
scatter foil (single scattering technique), when small fields are requested, or two
scatter foils (double scattering technique), when a broader beam is preferable [75].
The beam must additionally be shaped according to the target volume. Usually,
collimators are used to adapt the field for each separate treatment angle [74]. An
illustration of the passive scattering technique is shown in Figure 3.5a.
The main advantage of passive scattering is that the change of energy between
the different layers is achieved much faster than the scanning technique. Con-
sidering that the whole field is delivered almost at once, the complete treatment
duration will also be shorter [76]. However, a large disadvantage of the passive
scattering technique is the fact that subsidiary dose to the patient may occur due
to the additional collimation material in the beam line. This can lead to more
nuclear fragments [74].
Pencil beam scanning
Pencil beam scanning uses magnets to deflect, focus and steer the charged particles
in the beam. The magnets consist of two dipoles, run by fast power suppliers; one
for horizontal steering and one for vertical steering. This way a narrow beam can
be used to “paint” the dose over the target, layer by layer. When one layer of
voxels has been irradiated, the energy of the beam is decreased, and a new layer
can be treated [77]. The voxels, or spots, can be irradiated one by one (discrete
spot scanning) meaning that the beam is turned off between the irradiation of
each spot. Another method is the so-called raster scanning technique where the
beam continuously irradiates while the dipoles are simultaneously steering the
beam [75]. In pencil beam scanning, it is highly important that beam intensities
and beam positions are monitored in order to ensure a safe and accurate delivery
of the dose to the patient [73]. The main advantage of pencil beam scanning is
its high dose conformity compared to the passive scattering technique, and as a
consequence, lower doses to healthy tissues may be achieved. There will also be no
additional dose due to nuclear fragmentation from beam shaping materials [74].
The method of pencil beam scanning is shown in Figure 3.5b.
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(a) Schematics of the passive scattering technique. Scattering foils are used for
beam broadening while a collimator is used for beam shaping.
(b) Illustration of the pencil beam scanning technique. Dipole magnets are
used to steer the beam in both the horizontal- and lateral direction.
Figure 3.5: The two main delivery techniques used in particle therapy [17].
3.3.4 The rotating gantry
By using fixed beams in radiation therapy, either a horizontal beam, a vertical
beam, or both, the direction of the beam relative to the patient may be manipu-
lated by rotating the treatment table in different angles, or by turning the patient
relative to the treatment table. However, by only rotating the patient and the
treatment table, there are some limitations. By delivering the beam via a rotating
gantry, and (optionally) simultaneously rotating the patient, a higher degree of
freedom for the beam delivery angles relative to the patient and the tumor can be
achieved.
The gantries in proton therapy are rather large mainly due to the big and
heavy magnets that are needed to bend the proton tracks with a sufficient radius
of curvature. For protons, this curvature is typically around 1.5 m. Gantries as
large as 10−15 m in length, with a radius of about 5−6 m and weighing as much
as 100−200 t are not uncommon [71].
3.4 Uncertainties in Particle Therapy
The finite range and sharp distal dose fall-off are the biggest advantages of protons
in radiation therapy [12]. However, these advantages are at the same time their
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biggest disadvantages with respect to uncertainties. The finite range and the
strong energy-range relation make the protons highly susceptible to tissue density
variations and uncertainties [21]. Further, the relatively high dose increase in
the Bragg peak and the sharp dose-response curve may result in a significant
change in the TCP and/or the NTCP. Keeping the uncertainties to an absolute
minimum in particle therapy can be challenging and must have a high priority.
Commercial treatment planning systems available today are not able to display
consequences of uncertainties for the treatment plans. A physician in treatment
planning must always be aware that the dose distribution displayed by the TPS
is not necessarily the actual dose distribution delivered to the patient, and must
therefore be able to make mental assessments of the consequences of the dose
uncertainties [7]. Additional margins for the proton beam range are typically
added for range uncertainty assessment. These margins often differ from treatment
center to treatment center, but are generally around 2.5−3.5 % of the proton range
with an additional 1 mm margin [21].
3.4.1 Patient alignment and setup
Acquiring images of the patient should be done in the same patient position as
for the actual treatment. Patients are often immobilized on the treatment table
in order to minimize patient movement. External markings on the patient’s skin,
in addition to bony anatomy or implanted fiducials can be used for alignment.
A well-executed patient positioning procedure is essential for the reduction of
uncertainties [70]. The accuracy of the patient position should be about 1−2 mm,
with an emphasis on avoiding nearby critical structures [7].
3.4.2 Tissue heterogeneities
Tissue heterogeneities can substantially alter the proton beam range. Therefore,
it is important to select beam directions that try to avoid anatomical regions of
the patient that contain complex or high-Z heterogeneities and large air cavities.
Beam directions that require protons to stop right in front of critical organs should
also be avoided [7]. It is not only the range of the proton beam that is affected
by tissue heterogeneities. Multiple Coulomb scattering is the main cause of Bragg
peak degradation and may alter the shape of the dose distribution by a factor not
negligible from a clinical aspect [29]. Nuclear scattering may also contribute to as
much as 5 % of the change in the width of the distal dose fall-off, but is however
only slightly dependent on the complexity of tissue heterogeneities [78].
Analytical treatment planning algorithms are not able to correctly predict the
Bragg peak degradation resulting from multiple Coulomb scattering, mainly due
to their simplified algorithms [21]. Heterogeneities in the patient can, therefore,
contribute to uncertainties in particle therapy.
3.4.3 CT conversion uncertainties
The relationship between the linear attenuation coefficient for photons, used to
obtain Hounsfield units during a CT scan, and the relative stopping power of
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protons is quite complicated and difficult to analytically evaluate with a sufficient
accuracy. The relative stopping power depends primarily on the elemental compo-
sition, the mean ionization energy, and the physical density, of the material. There
are two main ways of converting HUs to relative stopping powers; the stoichiomet-
ric method [67] and the direct-fit method [79]. Without going into details, both
methods rely on converting Hounsfield units, acquired in a CT scanner using pho-
tons in the kilovoltage range, to relative proton stopping power. This conversion
is not trivial and can lead to uncertainties. The acquisition of the HUs themselves
can also lead to uncertainties as these units depend on the CT scanner’s tube
voltage, filter and other machine variables [66].
3.5 Monte Carlo Simulations
The Monte Carlo (MC) method is considered the most accurate procedure of sim-
ulating particle interactions in a medium [32]. By applying random sampling of
possible outcomes of different interactions and physical processes calculated from
probability distributions, the MC method can mimic real life interactions at the
atomic level on a particle-by-particle basis. The probability distributions are ob-
tained from experimental measurements or from models of particle transportation.
The particles are simulated one by one, a single step at the time, where a prob-
ability distribution is sampled from, at each separate step. The physical event
(absorption, annihilation, direction change, energy change etc.) occurring at each
step determines the next step of the particle. If secondary particles are produced,
these need to be tracked as well. After a particle, in addition to possible secondary
particles, has been absorbed, a new particle can be simulated [7].
In order to achieve a given accuracy in MC simulations, a sufficient number
of particles must be simulated. The precision of Monte Carlo results depends on
the number of histories (N) and is proportional to the function 1/
√
N . Therefore,
by increasing the number of histories, the computation time will also increase,
possibly making the MC simulation very time-consuming. The uncertainty of a
MC simulation also depends on the number of steps each particle takes. In dose
calculation, the maximum step size is limited by the CT voxel size. The reason for
this is that the physical processes that can occur are typically different for each
voxel because the material composition and density are different. A possibility
to decrease the computation duration would be to combine voxels and averaging
the material composition and density between them. Another method would be
to limit the particle tracking, meaning that if, for example, a secondary electron
has an energy below a certain value, the dose will be deposited at the point of
emission rather than to track the whole trajectory of the electron [71].
There are several different Monte Carlo codes available for dose calculation.
Most of them were developed in physics laboratories and later adopted for medical
use. As this project will use FLUKA [40, 41], a general purpose Monte Carlo tool,
for its simulations, this specific MC tool will be further outlined below.
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FLUKA
FLUKA is a multipurpose Monte Carlo code that can simulate the interaction
and propagation of about 60 different particles with high accuracy. This includes
photons and electrons from 1 keV to several thousands of TeV, hadrons up to
20 TeV, neutrinos and muons of any energies, among several other different parti-
cles. FLUKA is also able to track particles in electric and magnetic fields. FLUKA
can be used for a range of different applications including proton and electron ac-
celerator shielding, calorimetry, dosimetry, detector design, cosmic ray simulations
and neutrino physics. Microscopic models are the basis of FLUKA where conserva-
tion laws are enforced at every single step to ensure consistency among all reaction
steps and reaction types. The results are checked and benchmarked to experimen-
tal data at single interaction levels. This enables predictions with a minimal set of
free parameters, and as a further consequence, results in complex cases and scaling
laws arise naturally from the underlying physical models, providing predictivity
where experimental data is absent [40].
The FLUKA input
FLUKA relies on an input file in order to perform simulations. The file is written
using an ASCII standard where the user can provide different commands, by using
the standard FLUKA cards. A typical structure of a FLUKA input file may be
as follows [40]:
 Titles and comments for documentation purposes.
 Description of the problem geometry.
 Definition of materials.
 Material assignments.
 Definition of the particle source.
 Definition of the requested detectors to score physical quantities as dose,
fluence, energy, etc.
 Definition of biasing schemes.
 Definition of problem settings such as energy cutoffs, step size, physical
effects not simulated by default, particles not to be transported, etc.
 Initialization of the random number sequence.
 Number of requested histories.
For more advanced simulation setups that the regular input file is not capable of
handling, a number of FLUKA user interface routines are available.
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CT images in FLUKA
FLUKA is capable of describing complex geometries in terms of voxels, i.e. small
parallelepipeds of equal size, forming a three-dimensional grid. This can be useful
when performing dosimetric calculations in FLUKA. Flair [80], FLUKA’s graph-
ical user interface is capable of handling the importation of DICOM CT images
directly (see the next section for an explanation of DICOM files). In the Flair
DICOM interface, the Hounsfield unit in each voxel can be converted to material
density and elemental composition using material tables provided by the user.
The default conversion tables in FLUKA are based on the work of Schneider et
al. [81], and further extended by Parodi et al. [82] (more information in section
4.8). By handling this information, Flair converts the CT images into a so-called
voxel file that can be further used in FLUKA for patient dosimetry.
For more information about the specifics of FLUKA, the reader is referred to
the FLUKA manual [83].
3.6 The DICOM File Format
There are many different medical equipment manufacturers, and therefore a stan-
dard format for storing medical information was needed. The standard DICOM
format simplifies the exchange of medical data between equipment and software
developed by different manufacturers. The DICOM files contain necessary infor-
mation needed to execute radiation therapy on patients. Everything from images
of the patient’s anatomy, to coordinates of the regions of interest, beam energies,
gantry angles and so forth. Flair is, as of version 2.1-8, only able to directly
import DICOM images, containing the HU information. All other information
necessary to perform dose recalculations in FLUKA must be manually converted
to a FLUKA readable format.
The DICOM files store information mainly by using datasets, which are derived
from dictionaries in Python. They are a collection of key-value pairs, where the
key is the DICOM tag, and the value is a data element(s). By using the Pydicom
library, these datasets are easily accessible. Below is a small excerpt of a DICOM
dose file showing how a DICOM file is structured. The first column gives the tag
numbers, the second provides the tag names, the third column specifies the data
types (string, integer etc.) while the fourth column represents the data element(s):
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Listing 3.1: ”Example of data and format of a DICOM RT Dose file.”
(0008, 0012) Instance Creation Date DA: ’20160416’
(0008, 0016) SOP Class UID UI: RT Dose Storage
(0008, 0018) SOP Instance UID UI:
1.2.826.0.1.3680043.8.176.2016416103318991.11.5678144388
(0008, 0060) Modality CS: ’RTDOSE’
(0008, 103e) Series Description LO: ’Beam dose(s) for plan
270dgProton’
(0008, 1090) Manufacturer’s Model Name LO: ’RayStation’
(0010, 0010) Patient’s Name PN: ’PHANTOM_1^WATER’
(0018, 0050) Slice Thickness DS: ’2’
(0020, 000d) Study Instance UID UI:
2.25.338943507792393627692024455029958395970
(0020, 0032) Image Position (Patient) DS: [’-124’, ’-124’, ’-124’]
(0028, 0008) Number of Frames IS: ’125’
(0028, 0010) Rows US: 125
(0028, 0011) Columns US: 125
(0028, 0030) Pixel Spacing DS: [’2’, ’2’]
(3004, 0002) Dose Units CS: ’GY’
(3004, 0004) Dose Type CS: ’PHYSICAL’
(3004, 000a) Dose Summation Type CS: ’BEAM’
(3004, 000e) Dose Grid Scaling DS: ’3.1164414806E-05’
(300c, 0002) Referenced RT Plan Sequence 1 item(s) ----
(0008, 1150) Referenced SOP Class UID UI: RT Plan Storage
(0008, 1155) Referenced SOP Instance UID UI:
1.2.826.0.1.3680043.8.176.2016416103318990.7.5040860386
---------
(7fe0, 0010) Pixel Data OB or OW: Array of 3906250
bytes
3.6.1 CT Image and RT Structure Set
The DICOM CT Image files contains information about the patient’s anatomy
acquired from a CT scan. The density information, necessary for treatment plan-
ning, is stored as HUs in a two-dimensional array, called a pixel array (NumPy
array). The CT images are stored as a series of files. One file for each planar slice
in the DICOM coordinate system’s z-direction, where each file contains a separate
pixel array. All files put together in the correct order result in a three-dimensional
grayscale image of the patient. Furthermore, information about the dimensions of
the pixel array, in addition to the size of each pixel and the position and orienta-
tion of the patient on the imaging table are contained in the DICOM CT Image
files. All the mentioned information is necessary to perform dose calculations.
A second DICOM file containing relevant information for radiation treatment
is the RT Structure Set. This file defines a set of regions of interest (ROI) that are
essential in radiation therapy, such as body contours, PTVs, GTVs and OARs.
Information about the coordinates of the structures and the corresponding color
codes for the delineation lines are located in this DICOM file. The structures can
Chapter 3. Treatment Planning and Delivery 35
for example be useful to visualize the dose deposited to PTVs and OARs and they
are also necessary in order to calculate dose volume histograms.
3.6.2 RT Plan and RT Dose
The DICOM RT Plan file is the main pillar for performing dose recalculations.
In this file, most information about the TPS calculated treatment plan is located.
This includes treatment beams, dose prescription, accessories used (range shifter,
lateral spreading device etc.), patient setup, gantry angles, isocenter position in
the DICOM coordinate system, along with much more.
The RT Dose files contain the dose distribution calculated by the TPS, along
with other dosimetric details. The dose is also contained in a pixel array, as for
the CT image. A single dose file is created for each field used in the treatment.
This means also that the dose pixel array is three-dimensional, as opposed to the
two-dimensional array of the CT images. TPSs also allow for exportation of an RT
dose file containing the dose distribution from all the treatment fields combined.
Information about the dose scoring regions along with the size of the scoring grid
is also located in the RT Dose files.
For more details on the DICOM standard, the reader is referred to DICOM -
Information Object Definitions by the National Electrical Manufacturers Associ-
ation [84].
3.7 Coordinate Systems
In this project, there were several different coordinate systems to consider when
performing coordinate transformations. These systems are outlined below.
3.7.1 The patient coordinate system
The patient coordinate system is defined by the International Electrotechnical
Commission (IEC) in IEC 61217 [85] as having the positive x-axis toward the
left arm of the patient, the positive y-axis towards the patient’s head, and the
positive z-axis towards the patient’s chest. The patient coordinate system follows
the orientation of the patient, meaning that if the patient is rotated relative to
the patient table, the coordinate system will rotate accordingly. The patient
coordinate system can be seen in Figure 3.6a.
3.7.2 The DICOM coordinate system
The DICOM standard coordinate system is defined with the positive x-axis toward
the left arm of the patient, the positive y-axis towards the patient’s back, and the
positive z-axis towards the patient’s head [84]. The DICOM coordinate system is
also dependent on the patient orientation. The origin of the DICOM coordinate
system is not necessarily located at the isocenter of the CT scanner. The location
of the origin is machine dependent and can differ from scanner to scanner. The
DICOM coordinate system is seen in Figure 3.6b.








(b) The DICOM coordinate system.
Figure 3.6: The patient- and the DICOM coordinate system. 3D rendering
of CT images from OsiriX [86]. Figures created by the author.
3.7.3 The treatment room coordinate systems
The different coordinate systems in the treatment room are also defined in IEC
61217 [85]. They are a set of systems that are described in relation to their
mother coordinate systems. The systems in the treatment room, not used in this
project, will not be explained. The fixed system is the uppermost system in the
treatment room hierarchy, where the isocenter is located at the origin. Its daughter
coordinate system is the IEC Gantry system. It coincides with the fixed system for
a gantry angle equal to zero. If the gantry rotates, the coordinate system rotates
with it. The isocenter for the gantry system is also located at it origin. The fixed-
and the gantry coordinate systems are shown in Figure 3.7.
3.7.4 Patient orientations
Patients located on the imaging (and treatment) table can be oriented in different
directions, depending on what orientation is the most advantageous for treatment.
The most common orientation is the head first - supine (HFS) orientation where
the patient’s head is positioned toward the front of the imaging equipment, facing
upwards. There are however seven more orientations which are shown in Figure
3.8.
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Figure 3.7: The coordinate systems in the treatment room: the fixed system
and the gantry system. Subscript f means fixed, and subscript g means
gantry, for the axes in the figure. These two correspond when the gantry
angle is zero. If the gantry angle, for example, were to be 90◦, the positive
z-direction in the gantry system would point in the same direction as the
positive x-direction in the fixed system [84].
Figure 3.8: The different patient orientations in radiation therapy. The most




The main purpose of this project was to develop a tool to enable FLUKA Monte
Carlo recalculations of dose distributions initially calculated by commercial treat-
ment planning systems (TPS). A further aim was to enable comparison between
the FLUKA and the TPS dose distributions. The tool had to be able to handle
data translation between the TPS and FLUKA which required transferring of the
treatment plan and imaging information, in addition to plotting and displaying
dose distributions. The TPS data, which are stored in the DICOM file format, was
read, extracted and translated using Python [87] (v2.7) programming language in
combination with the Pydicom [88] (v0.9.7) library. To plot and compare two-
dimensional dose distributions, in addition to one-dimensional dose curves and
dose volume histograms, Python was used in conjunction with the NumPy [89]
(v1.8.2) and Matplotlib [90] (v1.3.1) libraries. The processes to obtain the input
data for FLUKA, and to perform comparisons are illustrated in Figure 4.1. DI-
COM files are exported from the TPS. These files are further run through scripts
that obtain treatment information needed by FLUKA to perform dose recalcula-
tions. FLUKA scores e.g. the dose which can be plotted as a two-dimensional
distribution transposed over the CT images. The DICOM files are directly utilized
to display the TPS dose distribution. Further, a visual comparison between the
dose distributions can be made. A comparison between the two dose distributions
can also be made by subtracting the TPS dose from the FLUKA dose. In addition
to the two-dimensional dose, one-dimensional depth dose curves and transversal
doses can be plotted, both from FLUKA and the TPS. The FLUKA dose can also
be converted to a DICOM RT Dose file which can be further used to create dose
volume histograms or be imported into different DICOM handling software.
4.1 Defining the FLUKA Coordinate System
When importing DICOM images into FLUKA, the patient will be oriented in
FLUKA according to the DICOM coordinate system only for the HFS orientation.
As a result, the coordinate system will not rotate according to the orientation of
the patient, which means that the positive y-axis in FLUKA will always point
towards the treatment table/floor. In FLUKA, the patient can be rotated and
translated to another coordinate system definition, if desirable. In this project,
it was chosen not to rotate the patient in the FLUKA coordinate system, and it
was further decided to use the isocenter definition of the gantry system (isocenter
at the origin). In conclusion, the coordinate system in FLUKA will consist of
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Figure 4.1: The workflow for dose verification with FLUKA. The custom
made scripts (green boxes) enable dose recalculation in FLUKA and com-
parison to the original dose distribution. Treatment plans (DICOM format)
from the TPS are run through the scripts which obtain relevant parameters
and information required by FLUKA.
the axis definition of the DICOM coordinate system for the HFS position and
the isocenter definition of the gantry coordinate system (see Figure 4.2). This
coordinate system was also chosen for the dose-displaying scripts in this project.
Since the patient was set not to rotate in the FLUKA system, coordinate trans-
formations had to be executed for the beam source itself according to the rotation
of the gantry. These transformations are further explained below and are only
valid for the HFS orientation. For the head first - prone (HFP) orientation some
modifications had to be made, not explained in this method. Other orientations
are not yet supported.
4.2 DICOM File Handling and FLUKA Input
File
After a TPS has been used to calculate and evaluate a treatment plan, the DICOM
files containing the treatment information, alongside the patient images, structures
and dose profiles, can be exported from the treatment planning system. However,
the naming convention used is in many cases not ideal for manual DICOM file
handling, as it can be problematic identifying the type of DICOM file. If DICOM
Chapter 4. Methods and Tools 41
Figure 4.2: The DICOM coordinate system is merged with the IEC Gantry
coordinate system to define the FLUKA system. The axes directions are
taken from the former, and the isocenter position from the latter, denoted
by the yellow dot. All orientations are HFS, gantry system is for 0◦ angle
and the isocenter position and patient position in the DICOM coordinate
system are only examples.
files are exported from a TPS, they are often further imported into another soft-
ware that takes care of the file handling. The tool developed in this project, on
the other hand, requires some manual handling of the DICOMs, mainly due to
the lack of a graphical user interface. Therefore, a script that evaluates all the
exported DICOM files was necessary. This script, called dicomSort.py, imports
all the DICOM files, identifies what type each respective file is (image, plan, dose,
structures), gives the files appropriate names, and stores them in a subfolder.
4.2.1 Automated creation of the FLUKA input file
To make the FLUKA recalculation procedure slightly more automated, the script
dicomSort.py, in addition to sorting and renaming the DICOM files, is able to
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automatically create the input file used by FLUKA based on relevant parame-
ters contained in the DICOMs. These parameters, including the FLUKA default
settings used, are explained below.
FLUKA defaults
FLUKA provides a set of default physics settings, making it simpler to choose the
best settings for specific applications. The pre-defined settings have all been op-
timized for a particular type of application. The script defines what FLUKA
defaults to be used for the recalculations. It provides the input file with a
HADROTHErapy DEFAULTS card. The HADROTHErapy settings are opti-
mized for hadron therapy physics, and are further outlined below:
 ElectroMagnetic FLUKA (EMF) on (transport of electrons, positrons and
photons).
 Inelastic form factor corrections to Compton scattering and Compton profiles
activated.
 Low-energy neutron transport on - thermal energies included (high energy
neutron threshold at 20 MeV).
 Fully analogue absorption for low-energy neutrons.
 Particle transport threshold set at 100 keV, except for neutrons (1× 10−5 eV).
 Multiple scattering threshold at minimum allowed energy, for both primary
and secondary charged particles.
 Delta ray production on - 100 keV threshold.
 Restricted ionization fluctuations on, for both hadrons/muons and electro-
magnetic particles.
 Ratio between hadron/muon upper- and lower interval limits of dp/dx mo-
mentum loss set at 1.03. Amount of the kinetic energy to be lost in a step
set at 2 %.
Maximum beam energy and particle type
Although the beam parameters for the treatment are separately imported using a
FLUKA user routine (see section 4.3), an energy larger than the maximum energy
of the beam is recommended to be issued to the FLUKA input file using the
available BEAM card. This is because FLUKA uses the provided energy to set
up tables for stopping powers, cross sections, etc. for the simulation [83]. If the
value is not provided, crashes may occur.
The energy provided to the FLUKA BEAM card is set to 20 MeV higher than
the maximum energy of the therapeutic beam. In addition, the radiation type
(protons or ions) is read from the DICOM RT Plan and added to the FLUKA
input file.
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CT image translation and isocenter correspondence
As previously outlined, the FLUKA coordinate system defined in this project is a
combination of the DICOM- and the IEC Gantry coordinate system (see Figure
4.2). The axes of the FLUKA system will automatically correspond to the DICOM
axes (for the HFS orientation) when importing the CT images. The coordinates
of the spot positions of the pencil beams used for treatment are defined using the
IEC Gantry coordinate system. It was for this reason having the origin defined at
the isocenter in FLUKA was desirable. In order to have corresponding isocenters,
the voxelized CT images must be translated to the correct position in the FLUKA
coordinate system.
The CT images can be imported directly using Flair, where they can be further
positioned using the so-called VOXEL card. However, the positioning coordinates
must be read and handled from the DICOM files. The necessary information for
the CT image translation is given in Table 4.1.
Table 4.1: The table describes the parameters necessary to perform correct
CT image translation in FLUKA in order to have isocenter correspondence






The x-, y-, and z-coordinates of the
upper left hand corner (center of the
first voxel transmitted) of the image,




Isocenter coordinates (x, y, z), in mm.
Specifies the location of the treatment
machine’s isocenter in the DICOM co-
ordinate system. Located in the DI-
COM RT Plan file.
Pixel Spacing
[PixSpace]
Physical distance in the patient be-
tween the center of each pixel, specified
by a numeric pair, in mm. Located in
the DICOM CT Image files.
Slice Thickness
[SliceThick ]
Nominal slice thickness, in mm. Lo-
cated in the DICOM CT Image files.
When the required parameters have been obtained, the CT voxel images can be
translated using the equations (4.1) below. Each equation refers to the position
of the origin of the FLUKA “voxel cage”, i.e. a region made of a single RPP
(rectangular parallelepiped) encapsulating all the voxels in the CT images. It is
highly important to translate the voxel cage correctly with millimeter precision,
in order to have a perfect isocenter correspondence between the two coordinate
systems.
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x =








ImagePos [2]− IsoPos [2]− SliceThick/2
10
.
The ImagePos and IsoPos are 3-tuples containing x-, y- and z-coordinates. The
z-coordinate (ImagePos [2 ]), also denoted slice location, must be acquired from
the first slice, i.e. the slice with the lowest z-coordinate, in order to remap the
patient correctly in the z-direction. The pixel spacing and slice thickness must
be divided by 2 and subtracted from the coordinates because, when expressing
their positions using coordinates, FLUKA refers to the corner of the voxels [91]
whereas the DICOM standard refers to the center of the voxels [84]. Each equation
is divided by 10 to obtain the answers in cm, the standard distance unit used by
FLUKA.
4.2.2 TPS scoring region and grid
In order to properly compare the dose calculated by FLUKA and the TPS, a
USRBIN card (defining scoring quantities and regions) in FLUKA should be cre-
ated to score the dose over the exact same region and using the same number
of scoring bins as the TPS, i.e. equivalent scoring grids. Table 4.2 provides the
parameters in the DICOM RT Dose files needed to obtain the scoring grid. The
Isocenter Position from Table 4.1 is also required.
After acquiring the information in Table 4.2, the scoring region in FLUKA can
be defined using equations (4.2).
Xmin =








DoseImagePos [2]− IsoPos [2]− DoseSliceThick/2
10
, (4.2)












The DoseImagePos are 3-tuples containing x-, y- and z-coordinates. Again the
pixel spacing and slice thickness must be subtracted and divided in half for the
same reason as above.
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Table 4.2: The table describes the parameters needed to score dose (or other
quantities) in FLUKA over the same grid as the TPS. All parameters are




Image Position (Patient) (Dose)
[DoseImagePos ]
The x-, y-, and z-coordinates of the up-
per left hand corner (center of the first




Physical distance in the patient be-
tween the center of each pixel in the








Number of columns in the dose grid,




Number of rows in the dose grid, i.e.
the number of scoring bins in the y-
direction.
Number of Frames (Dose)
[DoseFrames ]
Number of frames in a multi-frame im-
age, i.e. the number of scoring bins in
the z-direction.
4.3 Translating the Treatment Plan Information
The next step was to create a procedure for importing the beam parameters of the
treatment plan into FLUKA using the SOURCE user routine. The framework of this
file was provided by N. Bassler [92] and was further modified by the author of this
thesis. The SOURCE routine is written in Fortran 77. It is used to sample primary
particle properties from distributions that are too complicated to be described
using the regular FLUKA input file [83]. Pencil beam scanning (PBS) is the
state of the art treatment method for proton therapy [93], and therefore the tool
developed in this project is only able to handle and process treatment plans for this
specific technique. The PBS DICOM RT Plan file contains information about each
spot used in the treatment, as the spot positions, weights, and sizes. The gantry
angles and other treatment specific parameters are also located in the plan file. By
using Python and Pydicom, a script called beamParam.py was developed. Its main
objective is to create a simple text file containing the beam parameters depicted in
Table 4.3. These variables are necessary to replicate the TPS calculated treatment
plan in FLUKA.
The Scan Spot Meterset Weights can be directly written to the text file
without any modification, whereas for the Nominal Beam Energies, the values
must be converted from MeV to GeV, the standard energy unit for FLUKA.
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Table 4.3: The parameters needed to import the TPS calculated treatment
plan into FLUKA. All parameters are obtained from the DICOM RT Plan,




Nominal Beam Energy The nominal beam energy at the re-
spective spot position. Unit is MeV.
Scan Spot Position Map
[ScanSpotPos ]
The x- and y-coordinates of the scan
spots. They are defined as projected
onto the isocentric plane in the IEC
Gantry coordinate system. Unit is
mm.
Scan Spot Meterset Weights A dataset of meterset weights corre-
sponding to scan spot positions. The
order of weights matches the positions
in Scan Spot Position Map.
Scanning Spot Size
[ScanSpotSize]
The scanning spot size as calculated
using the full-width half maximum
(FWHM), specified by a numeric pair.
The size is measured in air at the
isocenter in the IEC Gantry coordinate
system. Unit is mm.
Gantry Angle
[gA]
Gantry angle of radiation source, i.e.,
orientation of IEC Gantry coordinate
system with respect to the fixed ref-
erence coordinate system. Unit is de-
grees.
Patient Position Specifies the orientation of the patient
on the treatment table, i.e. if the pa-
tient was oriented in a head-first supine
position or otherwise. Located in the
DICOM CT Image files, and the RT
Plan file.
4.3.1 Transformation of the beam direction
By default, a particle beam along with its spatial characteristics, is referred to as
a beam going in the positive z-direction in the FLUKA coordinate system [83].
As mentioned, the DICOM coordinate standard axes directions were chosen to
be used directly in FLUKA, meaning that a beam going in the z-direction will,
in most cases, not be correct. A patient located on a treatment table receiving
radiation therapy will be irradiated by a beam in the xy-plane according to the
DICOM coordinate system, at least for treatments applied using a gantry. To
simulate a rotating gantry in FLUKA, the position of the radiation source must
be transformed according to the angle of the gantry as explained in the next sub-
section. It is therefore also necessary to transform the beam direction in FLUKA
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depending on where the source is located in relation to the patient. This can
be done using the FLUKA BEAMPOS card or directly in the FLUKA SOURCE
routine. The two parameters in the SOURCE routine that must be changed are
the so-called TXFLK and TYFLK, where the former is the direction cosine of
the beam with respect to the x-axis in the FLUKA coordinate system, and the
latter is the direction cosine of the beam with respect to the y-axis in the same
coordinate system. By utilizing simple trigonometry, the direction cosines can be
calculated using the equations (4.3) below:
TXFLK = cos(flkAng) ,
TY FLK = cos(gA) , (4.3)
where the gantry angle (gA) can span from 0◦ − 360◦. fklAng is a variable angle




gA + 90◦, if 270◦ < gA ≤ 360◦ or 0◦ ≤ gA ≤ 90◦
270◦ − gA, if 90◦ < gA ≤ 270◦ . (4.4)
Figure 4.3 shows an example of a beam direction transformation. It displays
the transformation of a beam source located at a gantry angle of zero degrees in
the FLUKA coordinate system. Without transforming the direction, the beam
will travel along the positive z-axis. By utilizing the formulas 4.3 the beam will
be defined as having a cosine equal to zero relative to the x-axis and a cosine of 1
relative to the y-axis, i.e. the beam direction becomes perpendicular to the x-axis
and parallel to the y-axis. This coincides with a gantry angle of zero degrees in
the FLUKA coordinate system (see also Figure 4.2). Another example is a gantry
angle of 180 degrees, TXFLK is still 0, TYFLK is then equal to -1, and the beam
direction will become anti-parallel to the y-axis.
4.3.2 Transformation of the spot positions and spot sizes
All spot positions and sizes in DICOM files are defined in millimeters and must
be converted to centimeters. In addition, further trigonometric transformations
must be performed because the axes of the FLUKA- and the gantry coordinate
system do not correspond. Moreover, as the gantry coordinate system rotates
with the gantry angle, the coordinates defined in this system will always be the
same, independent of the gantry angle. The FLUKA coordinate system is however
fixed; therefore, the coordinates of the spot positions and the direction of the size
extension of the spot sizes must be transformed according to the gantry angle.
Scan spot positions
Transforming the y-coordinates of the scan spot positions is straightforward, as
the only difference in this relation is that the y-coordinates in the gantry system
will be equal to z-coordinates in the FLUKA system. This is true for every gantry
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Figure 4.3: Transforming the initial FLUKA beam from going in the z-
direction to travel along the positive y-axis.
angle, as the FLUKA z-axis will always be oriented in the same direction as the
gantry y-direction.
The x-position in the gantry coordinate system must be distributed in the
xy-plane in the FLUKA system depending on the gantry angle, i.e. depending
on where the radiation source is located in relation to the patient. Therefore,
one spot coordinate in the xy-plane in the FLUKA system is created from the
single x-position in the gantry system. In addition, the distance from the source
to the isocenter must be added to the spot position in the xy-plane. The follow-














The SpotPosX , SpotPosY , and SpotPosZ are the spot coordinates in the FLUKA
coordinate system, the ScanSpotPos [0] and ScanSpotPos [1] are the x- and y-
coordinates, respectively, as defined in the gantry coordinate system, and r is the
distance from the radiation source to the isocenter, which is added to SpotPosX
and SpotPosY depending on the gantry angle.
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Scanning spot sizes
The transformation of the spot sizes (FWHM) is quite similar. The spot size in
the y-direction in the gantry coordinate system can, by the same reasoning as
above, be directly transformed to the z-direction of the FLUKA system. The spot
size in the x-direction must be distributed in the FLUKA xy-plane, again by the











The FWHMx ,y,z are the spot sizes in the FLUKA coordinate system, the
ScanSpotSize[0] and ScanSpotSize[1] are the spot sizes in the x- and y-directions,
respectively, as defined in the gantry coordinate system.
To simulate an extended spot size in FLUKA, for each sampling of a particle,
the initial spot position for the particle is read. Added to this spot position is
the FWHM divided by a factor 2
√
2 ln 2 to obtain the standard deviation. This
standard deviation is further multiplied by a FLUKA defined Gaussian distribu-
tion. As a consequence, when a particle is sampled, its position will be Gaussian
distributed around the spot position, thereby mimicking an extended spot size.
See equation (4.7) for a mathematical explanation:





× RGAUSS . (4.7)
The XFLK (NPFLKA) is the FLUKA simulated spot position for each sampling
of a certain particle NPFLKA and RGAUSS is a random Gaussian distribution.
The same formula is applied for the y- and z-positions as well.
4.4 Displaying the Dose Distribution
In order to properly compare the calculated dose distributions from the TPS and
FLUKA, displaying the distributions using the same method and software was
necessary. Three python scripts called tpsScore.py displaying the TPS dose
distribution, flukaScore.py displaying the FLUKA recalculation of the dose dis-
tribution, and compFLKTPS.py displaying the difference of the dose calculated by
the TPS and FLUKA, were developed. The purpose of these scripts was to plot
the dose distribution as a 2D color wash transposed over the CT images, in ad-
dition to plotting the delineated volumes of interest on the images. Scripts for
plotting lateral- and longitudinal dose curves were also created. The Matplotlib
library was selected for the task of displaying the doses. The dose distribution
is displayed using three different main plotting functions, one for the CT image,
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one for the dose distribution, and one for the delineated structures. As all three
scripts follow the same principles explained below, there will not be a separate
section for each script. However, a subsection prevails in the end, outlining the
main differences.
4.4.1 CT images
The CT HU information is located in the already mentioned two-dimensional
pixel array. These CT units are plotted using a pre-defined grayscale color scheme
from Matplotlib. The CT grid makes up the basis for the dose display plot,
meaning that the plot of the dose and the structures must follow the same grid
and extension as the CT image. The following equations define the minimum and

















CtColumns and CtRows are defined as the number of columns and rows in the x-
and y-direction of the CT image, respectively. This information can be found in
the DICOM CT Image. Subtraction of half the pixel value is necessary because
the ImagePos refers to the position in the middle of the pixel, and thus when
defining the minimum values for the axes, the minimum value must be defined at
the pixel corner. Division by 10 is done in order to obtain answers in centimeters.
4.4.2 Dose distribution
In order to reduce the amount of binning information for the treatment simulation
in a TPS, the dose distribution is typically scored on a grid with larger dimensions
than the CT image. It is therefore necessary to interpolate the dose grid equal to
the size of the CT grid and remap the dose distribution to the correct position.
All parameters needed to perform the interpolation are contained in Table 4.2.
By defining maximum- and minimum values in the x- and y-direction for the dose
grid, it will be forced to follow these definitions. The following formulas is used:

















The parameters used in the equations are exactly the same as for equations (4.8),
except that they refer to the dose image and not the CT image. Division by 10 is
done in order to obtain answers in centimeters.
The dose distribution must additionally be interpolated in the z-direction. The
script, therefore, evaluates the fractional distances from the two slices in the dose
distribution that are closest to the CT slice that is being plotted. From these
two slices of dose, a single dose distribution can be created by multiplying each of
these slices with its respective fractional distance.
As treatment planning systems remove doses located outside the patient, it is
desirable to do the same for the FLUKA calculated dose, making visual compar-
isons simpler. Therefore, the script obtains the coordinates of the external region
of interest (the patient outline). It further evaluates if the calculated dose is lo-
cated outside or inside the patient. If parts of the dose are outside the patient,
the dose at these locations will be set to zero.
Normalizing the dose distributions
In order to compare dose distributions between FLUKA and the TPS, the dis-
tributions must be normalized. Not all TPSs used in this project provided the
number of particles used for treatment. This raised a problem to perform proper
normalizations. FLUKA calculates the dose per primary particle, and if the num-
ber of particles used in the TPS dose calculation is available, the number can be
multiplied by the FLUKA dose to obtain the total calculated dose compared to
the TPS. If the number of particles was not provided, it was chosen to perform
geometrical normalization [31]. The dose in both the TPS and FLUKA is then
normalized to the average dose of the 1000 closest voxels surrounding the cen-
ter position (the isocenter) of the target volume. The normalization is based on
the assumption that in this region the differences between the FLUKA dose and
the TPS dose are minor. This yielded acceptable results for the purpose of this
project, but normalizing using the number of treatment particles should be done
in order to perform proper comparisons.
4.4.3 Delineated structures
It is highly desirable to be able to display delineated regions of interest (ROI) in the
patient due to the fact that visual evaluation of the dose received by the target
volume(s) and OARs thereby becomes clearer. Parameters needed for plotting
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structures are given in Table 4.4, which are all located in the DICOM RT Structure
file.
Table 4.4: Coordinate- and color information of delineated
structures (ROI), needed for plotting.
Tag name Tag description
Contour Sequence Sequence of the contours defining
ROIs. The array consists of ROI
coordinates in the following format
[x1, y1, z1, x2, y2, z2, . . . , xn, yn, zn].
ROI Display Color RGB triplet color representation for
ROIs, specified using the range 0−255.
The user performing the plotting is provided with a list of the available struc-
tures, and can choose which ones to be shown on the CT image. The script loops
over all the coordinates, plots each point and further draws a line between the plot-
ted points. This line is drawn using the same color as defined for the respective
ROI.
4.4.4 Plotting the FLUKA dose distribution and the dose
difference
Plotting the dose distribution calculated by FLUKA, uses practically the same
method as used for plotting the TPS dose distribution. The main difference is that
FLUKA scores the dose utilizing a Fortran matrix, which is formatted differently
compared to the three-dimensional NumPy array used by the DICOM files. The
conversion is, however, relatively straightforward.
Plotting the dose distribution is performed by importing both the dose distri-
butions from the TPS and FLUKA into the script. By subtracting the TPS dose
distribution from the FLUKA dose distribution, the residual dose can be trans-
posed on the CT images, yielding positive values where FLUKA has calculated
higher doses, and negative values for higher doses calculated by the TPS. For the
geometrical normalization, the unit for the dose difference [%], is expressed as
a percentage of the average dose to the PTV, i.e. the normalization dose. For
normalization by using the number of treatment particles, the unit for the dose
difference is the respective dose unit used (Gy or Gy(RBE)).
4.5 FLUKA Dose to DICOM File and Dose Vol-
ume Histograms
By converting the dose from the FLUKA Fortran matrix to the same format as
the DICOM dose pixel array, it is possible to further create a separate DICOM
RT Dose file containing the FLUKA recalculated dose. This DICOM file is very
versatile as the file can be imported into numerous types of software that are
able to read and handle DICOM files. For example, by importing the FLUKA
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recalculation into the same TPS as the dose was initially calculated by, the TPS’s
powerful tools for dose evaluation, creation of dose volume histograms and dose
comparisons, can be exploited.
The Pydicom library has the ability to change the data elements associated
with each DICOM tag. This means that by writing a few lines of code, the
pixel array containing the originally TPS calculated dose distribution can be ex-
changed with the FLUKA recalculated dose distribution and saved as a new DI-
COM file. To make the FLUKA DICOM RT Dose file consistent with the regular
TPS dose DICOM files, the doses outside the patient are removed. By creating
DICOM files of the FLUKA dose, voxel-by-voxel comparisons to the original dose
distribution can also be performed, and fine grid dose differentials can be obtained.
In this project, the RayStation treatment planning system was used for creating
dose volume histograms (DVH). The RT Dose files from FLUKA and the TPS,
along with the RT Structure file were imported into RayStation which performed
the DVH calculations. The TPS created a .dvh file (regular ASCII file) containing
volume- and dose values. This .dvh file was exported and further imported into a
developed script that read the file and plotted the DVHs.
4.6 Creation of Water Phantom DICOMs
In order to test the developed tool on simple radiation plans, DICOM CT images
for three separate water phantoms were designed. The phantoms were created
using Dicomutilis [94], a set of utilities for working with DICOM files. They were
defined as having pixel sizes of 1 mm and a slice thickness of 2 mm, resulting in
150 CT slices containing images of 300× 300 pixels for each phantom.
A 30×30×30 cm3 homogeneous water phantom was defined (all voxels having
HU = 0). Further, a 5× 5× 5 cm3 box-shaped PTV, also consisting of water, was
defined in the middle of the phantom. Rectangular OARs (2 × 5 × 5 cm3) made
of water were placed at distances 0.5, 1 and 2 cm to the right of the PTV, with
the idea of a beam coming from the left i.e. going in the positive x-direction. An
additional OAR, of the same size, was added along the beam, just outside the
location of where the beam was intended to irradiate. The idea of the OARs was
to evaluate doses located outside the target volume and in low-dose regions.
The same phantom setup was chosen for the two remaining water phantoms,
only in these cases, were inhomogeneities added. For both phantoms a 2.5 ×
2.5× 2.5 cm3 box having a HU unit of 1000 and -1000 to represent bone and air,
respectively, were placed between the PTV and the water phantom edge, covering
half the entrance area of the beam. See Figure 4.4 for water phantom illustrations,
along with the delineated structures.
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(a) (b) (c)
Figure 4.4: The defined water phantoms and delineated structures. (a)
shows the homogeneous water phantom, (b) shows the phantom with the
bone volume, while (c) is the phantom containing an air cavity. The red
box in the middle indicate the PTV, whereas the rectangles are the OARs
in blue, yellow, pink and green.
4.7 Handling of Treatment Plans
4.7.1 Water phantom irradiations
All three water phantoms were imported into RayStation (v4.6), by RaySearch
Laboratories, for treatment planning. The same treatment plan was applied for all
the phantoms. A homogeneous physical dose of 70.00 Gy delivered in 35 fractions
was prescribed to the PTV. The radiation dose was delivered using a single 270◦
beam, i.e. a beam going in the positive x-direction in the phantom coordinate
system. Objectives and restrictions given for the optimization process can be seen
in Table 4.5. External comprise the whole water phantom volume, excluding other
delineated structures.
Table 4.5: Plan objectives for the water phantom irradiation plans.
Region of interest Objective Weight
PTV Min DVH: 70.00 Gy to 100 % volume 1.0
PTV Max dose: 71.75 Gy 2.0
External Max DVH: 35.00 Gy to 5 % volume 1.0
External Max dose: 56.00 Gy 3.0
OAR 0.5cm Max DVH: 7.00 Gy to 30 % 0.5
OAR 0.5cm Max DVH: 21.00 Gy to 10 % 0.5
It should be noted that the created water phantom plans are not necessarily
clinically optimized, but the treatment plans did, however, yield acceptable results
to be used for the purpose of recalculating the plans in FLUKA.
The physical dose was scored over the whole water phantom where the scoring
grid was defined to have pixel sizes of 2 × 2 mm2 as well as a slice thickness of
2 mm.
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4.7.2 Cranio-spinal irradiation
Cranio-spinal irradiation (CSI) is one of the most technically challenging treatment
planning and delivery procedures due to the complex-shaped and large target
volume [25]. CSI is a radiation treatment for cancer in the central nervous system,
where the whole spine and brain are irradiated. 20 − 30 % of all cancer diseases
in pediatric patients are due to central nervous system malignancies where a large
fraction of this is medulloblastoma. Because the target volumes are close to a
number of critical organs, side effects may occur following treatment, and it has
been found that there is significant increase in risk of developing secondary cancer
after medulloblastoma treatment [95]. For this reason, an IMPT CSI plan was
chosen for Monte Carlo recalculations.
The proton plan was provided by C. Stokkev̊ag [25]. The plan was calculated
in SIEMENS Syngo RT Planning TPS at the National Centre of Oncological
Hadrontherapy (CNAO). A large advantage of using Syngo as opposed to RaySta-
tion in this project, was that the number of particles used for each treatment field
was available, thereby making the normalization of the dose in FLUKA straight-
forward. The patient, an 11-year-old boy, was administered a physical dose of
21.27 Gy (biological effective dose of 23.40 Gy(RBE)) in 13 fractions to the PTVs.
Three fields were applied in a straight angle to the spine, and an additional two
opposing cranial treatment fields were delivered to the patient’s brain at angles of
15◦ relative to the treatment table. The patient was located on the treatment ta-
ble in a head first - prone position, and the treatment table was rotated in order to
treat the patient from the desirable angles. Objectives given for the optimization
process can be seen in Table 4.6. The number of particles administered for each
beam is given in Table 4.7. Cran1 and Cran2 are the cranial fields while Spin1,
Spin2 and Spin3 are the treatment fields applied to the spine.
Range shifters and range modulators were also used in the treatment plan
(CNAO beam line specifics) having water equivalent thicknesses of 31.44 mm and
2.00 mm, respectively. As this was the only information available concerning the
CNAO beam line, the range shifters had to be modeled in FLUKA as slabs of
water.
Table 4.6: Plan objectives for the CSI plan.
Region of interest Objective Weight
Brain (PTV) Prescription dose: 23.40 Gy(RBE) 1.0
Spine (PTV) Prescription dose: 23.40 Gy(RBE) 1.0
Esophagus (OAR) Max dose: 10.00 Gy(RBE) 1.0
Thyroid (OAR) Max dose: 5.00 Gy(RBE) 1.0
Eyes (OAR) Max dose: 5.00 Gy(RBE) 1.0
Trachea (OAR) Max dose: 5.00 Gy(RBE) 1.0
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Table 4.7: Number of primary protons for the CSI plan.






4.8 FLUKA Simulation Setup
All simulations in this thesis was conducted with FLUKA (v.2011.2c.4). The
conversion from Hounsfield units to density and material composition already
implemented in FLUKA was used. The conversion in the HU range between -
1024 to 1600 is based on the work of Schneider et al. [81] as a result of an analysis
of 71 human tissues. The conversion curve has been further extended by Parodi et
al. [82] for the HU range between 1600 and 3070. The final result is 27 groups of
different materials; 1 group for air, 1 group for lung tissue, 7 groups for soft tissue,
15 groups for skeletal tissues and 3 groups of high-Z materials. Within each group,
the material composition is preserved, while the material density scales with the
HUs. The calibration curve from HU to material density used in the simulations
is shown in Figure 4.5.

















Figure 4.5: The calibration curve for HU to material density used in the
simulations.
For the phantoms, the stopping power in water in FLUKA was scaled to ob-
tain correspondence with RayStation. In order to achieve unbiased comparisons
between the two systems, stopping powers should be matched [38]. A FLUKA
CORRFACT card was added which has the ability to scale the stopping power
density for selected materials. A scaling factor of 1.005 was set for the water phan-
toms. The value was based on test simulations and further comparisons between
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the depth dose curves for FLUKA and RayStation. For the CSI plan, no attempt
was made to calibrate FLUKA and the TPSs as this was beyond the scope of this
project. To achieve good accuracy, the stopping powers would have had to be
matched for all materials defined in the simulation [35]. This would have become
problematic, especially considering that the TPS the plan was calculated in was
not available for the author. However, it was not necessary to match the stopping
powers in order to test the developed scripts.
Most of the relevant FLUKA input cards were added automatically by the
scripts as previously explained. The energy spread had to, however, be defined
manually, as this is a treatment machine specific parameter [96] that is not located
in any DICOM file. As this value was not available for any of the treatment
plans, the FWHM of the energy spread was set to 0.8 % of the respective beam
energy for all FLUKA simulations. The choice of this value was based on trial and
error FLUKA simulations on a homogeneous water phantom initially calculated in
RayStation. An energy spread of 0.8 % yielded an adequately similar SOBP for the
two systems. The value was also somewhat in agreement with Hsi et al. [97], who
have reported an energy spread for cyclotrons (after passive range modulation)
between 0.8 % and 7 %, depending on the beam energy and modulating material.
This does, however, not necessarily mean that the value was correct, especially
not for the Syngo simulations.
The water phantom treatment plans were all simulated using 10 million parti-
cles per CPU thread, using 4 threads per beam over 5 cycles. This yielded mean
statistical errors below 1 % for the PTV, and below 10 % in low-dose regions. For
the CSI plan, each separate field was simulated using 10 million particles per CPU
thread, using 2 threads per beam over 1 cycle. The mean statistical errors were
below 2 % for the PTVs and below 10 % in regions with lower dose. However, for
regions with very little dose, the errors increased rapidly.
Scoring
Treatment planning systems calculate the water-equivalent dose, or dose-to-water,
Dw. This is because traditional treatment planning systems model the human
body as water with varying mass density, electron density or stopping power [98].
Arguments for reporting dose-to-water are that a human mostly consists of water
(about 60 % [99]), all clinical experience is based on dose-to-water, and commis-
sioning, quality assurance and absolute dose measurements are done in water. On
the other hand, Monte Carlo tools originally calculate the dose to material, Dm,
as they take into account material properties such as ionization potentials and
material compositions.
Therefore, it was desirable to calculate the dose-to-water in FLUKA for com-
parison purposes. This can be achieved by using the FLUKA user routine FLUSCW.f,
a routine used for weighting e.g. particle fluences. Dose-to-water can be calculated
by scoring the fluence of the charged particles in a given medium. By multiplying
the fluence by the LET in water for the charged particles, the dose-to-water can
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be obtained. See equation (4.10).




where Dw is the dose-to-water, Φm is the fluence of the charged particles in the
given medium, ρw is the density of water and LETw is the linear energy transfer
in water.
In FLUKA, the fluence of all charged particles was scored over the same region
as the TPS, using a USRBIN card. The fluence was further multiplied by the LETw
using the FLUSCW.f user routine, thereby obtaining the dose-to-water.
Comparing dose-to-water and dose-to-medium
Dose-to-water and dose-to-medium report different magnitudes of doses as the
energy loss of particles depends on the elemental composition of the medium [35].
To study the difference between the two, a second scoring card was added to the
FLUKA simulation for the CSI plan that scored dose-to-medium. It was scored
using a regular dose USRBIN card in FLUKA, over the same region as the dose-to-
water was scored. The Dw results were converted to a FLUKA DICOM RT Dose
file and run through the script compFLKTPS.py along with the FLUKA scoring
matrix of the Dm.
To further evaluate the difference between the two scoring methods, a 30×30×
30 cm3 phantom consisting purely of voxels with a HU unit of 1000 to emulate high-
density bone, was created using Dicomutilis. A SOBP covering a 5×5×5 cm3 PTV
in the middle of the phantom was defined. The plan was simulated in FLUKA,
scoring both dose-to-water and dose-to-medium.
Chapter 5
Results
5.1 Dose Verification and Recalculations
The main result of this work is the developed Python based tool. The results
presented in this chapter demonstrates its ability to recalculate doses from simple
treatment plans as well as complex clinical multi-field plans. The TPS radiation
plans from the previous chapter (water phantom irradiations and CSI) were run
through the Python scripts and FLUKA Monte Carlo recalculations were con-
ducted. The main focus of the results in this chapter will be to demonstrate the
functionality of the developed tool. The results will not focus on differences be-
tween the TPS and FLUKA calculated doses i.e. perform benchmarking of the
TPS, as this is beyond the scope of this project. However, aspects that are im-
portant to consider when performing validation of TPS calculated doses, will be
emphasized.
In this section, two-dimensional dose distributions, dose profiles in the longi-
tudinal and lateral directions, in addition to dose volume histograms, are shown.
All results marked DTPS are doses directly reported from the respective treatment
planning system, while all results tagged DMC are FLUKA Monte Carlo recal-
culations of the doses. Results showing DMC − DTPS are plots where the TPS
calculated dose has been subtracted from the FLUKA calculated dose, in order to
better depict any differences. All plots are created using scripts developed in this
project, if not stated otherwise.
5.1.1 Water phantom irradiations
For the three water phantoms, all displays of the two-dimensional dose distribu-
tions and dose differences in Figure 5.1, shows the slice located in the middle of
the phantoms (z = −0.1 cm). The same slice is also shown for the longitudinal
depth dose curves. Further, the lateral dose curves at x = −0.1 cm are plotted.
For the two-dimensional dose distributions, including the dose difference plots,
the distributions are normalized to the average dose in the middle of the PTV
(red box) on the assumption that the doses reported by FLUKA and RayStation
are highly similar in this region. The lowest doses displayed, for all 2D-plots, are
set to 0.1 % of the PTV dose. The red parts of the dose difference plots are areas
where FLUKA calculates a higher dose, while the blue parts depict higher doses
from RayStation. All lateral- and longitudinal dose curves are normalized to the
maximum dose calculated by RayStation at the respective x- or z-position.
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Figure 5.1: Two-dimensional dose distributions on water phantoms. First
row is the homogeneous water phantom, second row is the phantom with
a bone region, while the third row shows the phantom with an air cavity.
The red box is the PTV, the green box is a defined OAR while the blue
rectangle is an OAR located 0.5 cm behind the PTV. For (c), (f) and (i),
dose differences between -0.1 and 0.1 % are set transparent, depicted as gray
dots.
Homogeneous phantom
Figure 5.1a and 5.1b display the two-dimensional dose distributions in the homoge-
neous water phantom, as calculated by RayStation and FLUKA. From the figures,
it is apparent that FLUKA calculates a marginally higher dose in the low-dose
regions at the outer parts of the dose distribution. The differences between the
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two dose distributions are better depicted in Figure 5.1c. There are some small in-
consistencies between the dose calculated by FLUKA and RayStation behind the
PTV. Immediately following the PTV, RayStation reports a higher dose, while
FLUKA reports a higher dose just inside the blue OAR. This may be due to an
incorrect matching of the stopping powers (see section 4.8), and the geometrical
normalization (section 4.4) could also cause some discrepancies. RayStation also
calculates a higher dose in the middle of the entrance region of the beam, while
FLUKA calculates a higher dose at the outer regions.
In Figure 5.2, the longitudinal- and lateral dose curves are shown. Also from
the longitudinal curves, it can be seen that RayStation calculates an overall higher
dose in the entrance region. The curve at the SOBP region is also smoother for
FLUKA, which may be due to an incorrect energy spread in FLUKA. The lon-
gitudinal curves further depict a better correspondence between the beam ranges
compared to the two-dimensional plot. In Figure 5.2b, showing the lateral dose
in the middle of the PTV, FLUKA calculates a marginally higher dose, most
pronounced in the outer regions.
Finally, Figure 5.3 displays the dose volume histograms for all the ROIs out-
lined in the water phantom. The OARs closest to the PTV receives a higher dose
according to FLUKA, while the OAR at the side of the beam also receives a higher
dose in the Monte Carlo simulation. For the PTV, the dose reported by FLUKA
is somewhat less homogeneous and a bit higher for a greater part of the volume.
The pink OAR located 2 cm behind the PTV is not visible in the plot, since no
significant amount of dose is received.
(a) Longitudinal depth dose curves
from FLUKA and RayStation.
(b) Lateral dose curves from
FLUKA and RayStation.
Figure 5.2: Dose profiles in the longitudinal- and lateral direction from
FLUKA and RayStation in the homogeneous water phantom.
Phantom containing a bone volume
When a bone region is introduced to the water phantom, it can be seen from
Figure 5.1d and 5.1e that the dose to the PTV becomes less homogeneous for
both FLUKA and RayStation. As before, FLUKA calculates a higher dose in the
outer regions of the beam. Further, looking at the dose difference in Figure 5.1f,
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Figure 5.3: Dose volume histograms for ROIs in the homogeneous water
phantom.
FLUKA calculates a noticeably higher dose inside the blue OAR, in areas where
the beam has penetrated the bone volume. In the upper region of the same OAR,
FLUKA still calculates a higher dose than RayStation, but of a lower magnitude
compared to the rest of the OAR. Inside the PTV, FLUKA typically calculates a
lower dose for areas behind the bone volume, while a higher dose is reported at
the part of the PTV where the beam has not penetrated the bone volume.
For the longitudinal dose curves in Figure 5.4a, similar doses, except for the
entrance region, is apparent. The lateral dose curves (Figure 5.4b) show a larger
dose at the outer regions of the radiation field.
The dose volume histograms for ROIs in the phantom are plotted in Figure
5.5. It is evident that a higher dose is received by the PTV according to FLUKA.
The overall doses to the OARs located behind the PTV have also increased, in
agreement with what the two-dimensional dose distributions show.
(a) Longitudinal depth dose curves
from FLUKA and RayStation.
(b) Lateral dose curves from
FLUKA and RayStation.
Figure 5.4: Dose profiles in the longitudinal- and lateral direction from
FLUKA and RayStation in the water phantom containing a bone volume.
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Figure 5.5: Dose volume histograms for ROIs in the water phantom
containing a bone volume.
Phantom with an air cavity
In Figure 5.1g-5.1h, the two-dimensional dose distributions, in addition to the
relative dose differences between FLUKA and RayStation, are shown. In this
setup, the phantom contains an air cavity (HU = -1000) at the same placement as
the bone region in the previous case. Even though the beam now has penetrated
deeper into the phantom, a lower dose than for the phantom with the bone volume,
is reported to the blue OAR. However, FLUKA and RayStation are in relatively
good agreement for the doses inside the OAR. This can be observed from Figure
5.1h, due to the absence of any dark blue or dark red spots. No noticeable dose
difference to the green OAR compared to the previous cases is reported. In the
PTV, FLUKA calculates a higher dose for most locations where the beam has
penetrated the air cavity, whereas RayStation reports a higher dose for areas not
located behind the air cavity.
Looking at the longitudinal dose profile in Figure 5.6, a lower dose to the distal
half of the PTV is calculated by FLUKA. As before, a higher TPS calculated
dose is reported at the beam entrance region. The lateral dose curves show a
somewhat less homogeneous dose reported by FLUKA, but are however else mostly
in agreement with RayStation.
The dose volume histograms in Figure 5.7 show that FLUKA calculates a
noticeably less homogeneous dose to the PTV. There is also a discrepancy between
the doses received by the OARs according to FLUKA and RayStation.
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(a) Longitudinal depth dose
from FLUKA and RayStation.
(b) Lateral dose curves from
FLUKA and RayStation.
Figure 5.6: Dose profiles in the longitudinal- and lateral direction from
FLUKA and RayStation in the water phantom containing an air cavity.



























Figure 5.7: Dose volume histograms for ROIs in the water phantom con-
taining an air cavity.
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5.1.2 Cranio-spinal irradiation
All doses in the following subsection are biological effective doses, Gy(RBE), i.e.
the physical dose, in Gy, multiplied by an RBE of 1.1. The dose distributions (and
dose differences) below 0.1 Gy(RBE) are set transparent. For the dose difference
plots, the red colored regions depict higher doses calculated by FLUKA, while the
blue colored regions mean higher doses reported by the TPS. The one-dimensional
dose curves are normalized to the maximum dose calculated by Syngo at the
respective y- or z-position.
Shown in Figure 5.8 are dose distributions, and dose differences, from three se-
lected slices of the spine, calculated by Syngo and further recalculated by FLUKA.
One slice is plotted from each of the three spinal fields (Spin1, Spin2 and Spin3).
FLUKA is able to recalculate the dose distributions, but it is however apparent
that the FLUKA dose has a noticeable pullback compared to the TPS dose. This
may be due to the lack of beam line implementation in FLUKA, as the pullback
is similar for all slices. It becomes even more evident in the dose difference plots,
especially for Figure 5.8c. Likewise as for the water phantoms, an overall higher
dose is reported by FLUKA at the outer regions. Note that the CT images have
been flipped along the x-axis. This was done to obtain correspondence with the
RayStation coordinate system (see section 5.3).
Figure 5.9 shows the dose distributions, and dose differences, for the two com-
bined cranial fields, at two separate locations in the head. Comparing Figure 5.9a
and 5.9b, the indicated pullback is noticeable, especially in the regions to the up-
per right and left of the delineated eyes. Apart from this, the dose distributions
are quite similar.
In Figure 5.10, the depth dose curves for the spinal fields are plotted. The
same slice locations as for the previous figures are shown. The shifted penetration
depths of the dose curves are obvious in these figures. The doses are normalized
to the maximum dose calculated by Syngo in the respective slice. Except for the
shift in the curves, they are in quite good agreement. Figure 5.11 further shows
the dose from the cranial fields plotted along the y-direction. FLUKA reports an
overall lower dose for both slice locations.
The lateral dose curves from the three spinal fields are shown in Figure 5.12.
The curves located at y = 6.77 cm are displayed for all three fields. The shapes of
the curves are relatively similar, but there are some differences, most prominent
in Figure 5.12a. Here, Syngo calculates a dose on the order of 10 % higher than
FLUKA at a lateral position of −18.2 cm.
Figure 5.13 shows dose volume histograms of regions of interest that were
prescribed dose goals or restrictions according to the DICOM RT Plan file, in
addition to the external ROI, called SkinOK. An overall lower dose is calculated
by FLUKA for all the delineated volumes. But this is mainly due to the pullback
in the FLUKA dose distributions, at least for the OARs, which are located after
the Bragg peaks of the beams. Since the beam simulated in Syngo penetrates
deeper into the patient, it is expected that the higher doses will be reported to
the OARs according to Syngo.
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Figure 5.8: Two-dimensional dose distributions of the spinal fields for the
CSI plan. Outlined are the spinal PTV (orange), esophagus (green), trachea
(yellow) and thyroid (blue). Dose differences between -0.1 and 0.1 Gy(RBE)
are set transparent, depicted as black dots.
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Figure 5.9: Two-dimensional dose distributions of the cranial fields for the
CSI plan. Outlined are the brain PTV (purple) and eyes (pink). Dose
differences between -0.1 and 0.1 Gy(RBE) are set transparent, depicted as
black dots.
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(a) Longitudinal depth dose curves from
FLUKA and Syngo at z = −14.4 cm.
(b) Longitudinal depth dose curves from
FLUKA and Syngo at z = 6.6 cm.
(c) Longitudinal depth dose curves from
FLUKA and Syngo at z = 21.6 cm.
Figure 5.10: Longitudinal depth dose curves of the
spinal fields for the CSI plan.
(a) Dose curves from FLUKA
and Syngo at z = 33.6 cm.
(b) Dose curves from FLUKA
and Syngo at z = 36.6 cm.
Figure 5.11: Dose along the y-axis of the cranial fields for the CSI plan.
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(a) Lateral dose curves from FLUKA
and Syngo of the lowest spinal field (Spin3).
(b) Lateral dose curves from FLUKA and
Syngo of the middle spinal field (Spin2).
(c) Lateral dose curves from FLUKA and
Syngo of the highest spinal field (Spin1).
Figure 5.12: Lateral dose curves of the spinal fields for the CSI plan.
Curves at y = 6.77 cm are displayed.





























Figure 5.13: Dose volume histograms for ROIs with prescribed dose goals
or restrictions for the CSI plan.
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5.2 Difference Analysis of Dose-to-Water and
Dose-to-Medium
This section presents differences between the scoring of dose-to-water (Dw) and
dose-to-medium (Dm). In Figure 5.14a the difference between the two dose-
reporting methods on a phantom consisting purely of bone, can been seen. Dose
differences below 4 % are set transparent. The dose-to-water is clearly higher for
all parts of the dose distribution. The same difference is also evident for the depth
dose curves in Figure 5.14b. The Dw is greater than the Dm by approximately
5 % along the whole curve.
4 6 8 10-4-8 -6-10
Dose [%] MediumWater
(a) (b)
Figure 5.14: Two-dimensional dose difference plot and depth dose curves of
dose-to-water and dose-to-medium scored in a bone phantom.
Figure 5.15 shows the difference between the two-dimensional FLUKA dose
distributions calculated as Dm and Dw for selected slices in the CSI plan. Dose
differences lower than 0.1 Gy(RBE) are set transparent. It looks like the Dw is
slightly higher for regions denser than water (HU > 0), while Dm is somewhat
greater for low density regions. This can, for example, be seen for some areas in
the lungs in Figure 5.15a (delineated in dark blue).
Further, looking at the depth dose curves in Figure 5.16, the dose-to-water is a
bit higher for most positions along the curve. Specifically, an increase in the dose-
to-water can be seen in Figure 5.16b, starting at a depth around 7.5 cm. Looking
at the same position in Figure 5.15b, one can see that the dose-to-water is higher
in this region, and this is also at an area where the spine is located. According to
H. Paganetti [98], Dw typically reports larger doses to dense material compared
to Dm.
Lastly, the dose volume histograms for the two cases are displayed in Figure
5.17. The dose-to-water is slightly greater for the ROIs, at least in the high-dose
regions (PTVs).
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Figure 5.15: Dose differences between dose-to-medium and dose-to-water for
the CSI plan, as calculated by FLUKA. Dose differences between -0.1 and
0.1 Gy(RBE) are not shown.
(a) Dose-to-medium vs.
dose-to-water at z = 8.4 cm.
(b) Dose-to-medium vs.
dose-to-water at z = 21.6 cm.
Figure 5.16: Longitudinal depth dose curves of dose-to-medium
and dose-to-water for the CSI plan, as calculated by FLUKA.





























Figure 5.17: Dose volume histograms for ROIs for dose-to-medium (MED)
and dose-to-water (H2O) for the CSI plan. Solid lines depict dose-to-water,
while dashed lines depict dose-to-medium.
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5.3 FLUKA DICOM Export
The FLUKA calculated doses can, by using the developed tool, be converted
into DICOM RT Dose files. This section demonstrates that the DICOM export
procedure performs well and shows some of the possibilities that opens up when
importing the FLUKA dose into the RayStation TPS. All the following figures
are obtained directly from RayStation. In the dose difference plots, warm colors
depict higher doses from the TPS while colder colors depict higher doses from
FLUKA.
In Figure 5.18 the same comparison as shown in figures 5.1a-5.1c is displayed,
however, in this case, the comparison has been conducted in RayStation. The
same slice location is shown (z = −0.1 cm), but the dose cutoff for the differences
is now set at 1.0 % of 70 Gy, which is the prescribed dose. Dose evaluation in
RayStation is possible in several planes i.e. the transverse, sagittal or coronal
plane.
Figure 5.18: Dose distribution comparison for the homogeneous water phan-
tom, conducted in RayStation. Differences below 1.0 % of 70 Gy are set
transparent.
It is also possible to import doses calculated by other treatment planning
systems into RayStation. The Syngo- and FLUKA doses for the CSI plan were
imported into RayStation along with the CT images and structures. In Figure 5.19
the dose distributions calculated by Syngo and FLUKA can be seen. The same
slice as in figures 5.8d-5.8f is displayed. The dose difference is cut off at 1.0 % of the
prescribed dose (23.4 Gy(RBE)). Figure 5.20 outlines the dose statistics for a few
selected volumes in the patient, while Figure 5.21 shows the FLUKA calculated
dose distribution in the transverse, coronal and sagittal plane as displayed by
RayStation.
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Figure 5.19: Dose distribution comparison for the CSI plan, conducted in
RayStation. Differences below 1.0 % of 23.4 Gy(RBE) are set transparent.
Figure 5.20: Dose statistics from Syngo and FLUKA for ROIs in the CSI
plan. The large discrepancies are mostly due to the reported FLUKA beam
pullback.
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Figure 5.21: Evaluation of the FLUKA recalculated dose distribution
for the CSI plan, conducted in RayStation.
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Discussion and Further Work
6.1 Dosimetric Verifications
The results in section 5.1 show that the tool developed in this project is successful
in importing treatment plans, calculated by clinically used commercial treatment
planning systems, into the FLUKA Monte Carlo tool for dose recalculation. This
includes extracting the relevant information for each pencil beam in the treatment,
and further transforming this information into a format readable for FLUKA. In-
terpolation of dose distributions and plotting of e.g. delineated structures performs
as expected. As a consequence, the tool enables display of two-dimensional dose
distributions in the transverse plane along with two-dimensional dose distribution
differences, in addition to lateral- and longitudinal one-dimensional dose curves.
Finally, dose volume histograms for both the TPS and FLUKA can be created,
and DICOM export enables Monte Carlo dose visualization in a commercial TPS.
For the homogeneous water phantom, the differences in the dose distributions
from RayStation and FLUKA were minor. A relatively similar homogeneous dose
was delivered to the PTV for both systems. For all the phantom irradiation
plans, including the CSI plan, higher doses were reported by FLUKA at the outer
regions of the beam. This is consistent with the findings of Howell et al. [100] who
showed that TPSs may underestimate out-of-field doses, increasing in magnitude
for longer distances. Another similarity for the phantoms was that a lower dose
was scored by FLUKA in the middle area of the beam. The reason for this was
not further explored; however, the geometrical normalization method for the water
phantoms may have resulted in this discrepancy. It was based on the assumption
that the average dose located at the center of the PTV was similar for the two
simulations. If this is not the case, the normalization may introduce high levels
of uncertainties. However, without knowing the number of particles used in the
treatment, nor the conversion factor between the monitor unit output and the
number of particles (this conversion factor can be obtained by measurements in
ionization chambers [71]), the geometrical normalization approach was decided
to be adequately accurate for the purpose of this project. For comparisons with
clinical accuracy, the FLUKA dose must be normalized properly.
When inhomogeneities were introduced into the phantoms, the differences be-
tween the analytical calculations and the Monte Carlo simulations increased. The
dose to the PTV became less homogeneous for both the phantoms containing a
bone- and air volume. The differences were largest for regions where the beam
had penetrated the inhomogeneities. As noted previously in this thesis, it is in
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regions containing inhomogeneities where Monte Carlo simulations are superior
compared to commercial treatment planning systems [15, 32–37].
Most apparent for the homogeneous water phantom, was the disagreement
between the calculated beam ranges for the two systems. The main reason for
this may be due to an incorrect matching of the stopping powers. The geometrical
normalization may also have contributed to the different ranges. And lastly, a lack
of beam line implementation in FLUKA may, in addition, have contributed to
the differences. The RayStation simulations were conducted using an IBA-based
nozzle design. No range shifter was selected to be used in the simulations, but
there may, for example, have been a vacuum window or other components in the
nozzle design, resulting in a decreased range of the simulated RayStation beam.
When looking at the dose difference plots and the depth dose curves for the
clinical cranio-spinal irradiation plan, there was an apparent difference between
the simulated ranges in FLUKA and the TPS. The range of the FLUKA simulated
beam was around 0.5 cm shorter than for Syngo. As no calibration between the
two systems was conducted, this may have introduced a change in beam range.
Ideally, a calibration curve between the Hounsfield units and relative stopping
powers should be implemented into FLUKA [35, 68]. While nuclear processes
scales with the density, electromagnetic processes must be furthermore adjusted
to reproduce the same dependence between the relative stopping powers and HUs,
used by the treatment planning system [82]. A method of matching stopping
powers between the TPS and a Monte Carlo tool can be found in [38].
In addition, both a range shifter and a range modulator were utilized for the
CSI plan. As previously mentioned, no information about the beam line and
nozzle used for the TPS simulation was available, except for the water equivalent
thicknesses of the modulator and range shifter. As a result, the range shifting
components had to be modeled in FLUKA as slabs of water, introducing additional
uncertainty. This may have been avoided with proper implementation of the range
modulator and range shifter. Other parts of the beam line geometry should also be
modeled in the Monte Carlo simulations in order to obtain correspondence with the
treatment planning system and treatment room [101, 102]. The decreased range
of the FLUKA beam introduced significantly lower doses to OARs and insufficient
dose coverage to the target volumes. Another reason, contributing to the reported
pullback from FLUKA, may have been the Hounsfield units outside the patient.
To minimize computation time, commercial treatment planning systems normally
assign a HU of -1024 (vacuum) for all regions outside the patient. This was
not done in this project. The voxel cage that encapsulates all the voxels of the
patient in FLUKA, was surrounded by vacuum. However, most voxels between
the vacuum and the patient (a length of approximately 15 cm) had a HU of
about -995, or less. The difference in HUs was moderate, but may nevertheless
have contributed to the observed range difference. Further work should include
addressing these issues.
A substantial advantage for the CSI plan was that the number of particles used
for treatment was available, and thus proper normalization could be performed
by multiplying the reported FLUKA dose by the original number of particles (see
section 4.4). To gain a true comparison between dose calculation methods and
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find the absolute difference, the normalization should be based upon the numbers
of particles given in the plan. Between 0.034 and 0.016 % of the initial number of
primary beam particles were simulated. This yielded mean statistical errors below
2 % in the PTVs and below 10 % for regions with lower doses (outside the treatment
fields). The errors did however increase rapidly for very low-dose regions. As a
statistical uncertainty of about 2 % in the PTV is required in a clinical setting [35,
103], it was concluded that the number of particles simulated in this project was
sufficient. The fraction of particles simulated was also in agreement the findings
of Verburg et al. [38], who have stated that a number of histories, that is 4-5
orders of magnitude below the number of particles used in the treatment plan,
will suffice to obtain accurate results. They further emphasize that the number of
histories should be increased if doses to regions far outside the treatment field are
of interest.
Results from the CSI plan also showed some minor differences between the
dose-to-water and dose-to-medium. Even though the differences were relatively
small, the same dose scoring methods should always be performed in order to
minimize uncertainties between the two systems. Siebers et al. [104] has for
photon radiation reported a difference of 1 % in soft tissue and over 10 % in dense
bone. Similar effects has been shown for protons by Jiang et al. [105]. This is in
compliance with the presented results for the simulated bone phantom irradiation,
where the reported difference between the two scoring methods was on the order
of 5 % for all parts of the phantom.
6.2 Further Potential for the Developed Tool
By importing clinically calculated treatment plans into a Monte Carlo simulation
tool, a number of possibilities open up for the evaluation of treatment quality
and analyzing different aspects of particle therapy. Treatment planning systems
are typically very restricted in which quantities they are able to score (in most
cases only dose). By using Monte Carlo tools for recalculation of treatment plans,
not only will a more accurate dose distribution be obtained [33], but for example
scoring of excess dose due to nuclear fragments [15], range verifications [82] and
linear energy transfer scoring [106] can be performed. This section will give a short
outline of some of the applications that the developed tool makes achievable, either
right away, or in the near future.
Linear energy transfer scoring
Even though a generic RBE value of 1.1 is used for proton therapy, it is well
known that this is only an approximation, as the RBE depends on dose, endpoint,
LET and other factors [107]. It has also been established that the RBE increases
at the distal end of the Bragg peak [108]. This is due to the increased LET
for low energy particles (Figure 2.6), and the RBE dependence on LET (Figure
2.7). The variations in LET and RBE are even more pronounced for carbon ions
[109]. A homogeneous dose distribution does not guarantee a homogeneous LET
distribution and may result in a varying biological effect to the tissue [107]. By
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mapping the LET variations in the human anatomy, the RBE dependence can be
more precisely determined, and the physical dose can be weighted accordingly.
The FLUKA Monte Carlo tool has the ability to score LET [110]. Thus, by im-
porting clinical treatment plans into FLUKA, the LET distributions in regions of
interest can be determined. The dose can further be biologically weighted accord-
ing to the more accurately determined RBE. And with some minor modifications,
the tool can also be used to evaluate the varying RBE for carbon ions.
Custom response models
In addition to calculating RBE and biological doses based on LET, it should
be relatively straightforward to couple FLUKA with models for normal tissue
complication probabilities (NTCP) and other endpoints such as e.g. secondary
cancer risk models.
The risk of developing secondary cancer is of concern in radiation therapy. By
converting doses received by different organs and regions in the body, to risks of
developing secondary cancers using dose-risk models, the risk distributions can
be displayed superimposed on the patient CT images, similar as for the dose
distributions. This was done by Zhang et al. [111] in 2015, by developing their
own risk models. They did the procedure by converting doses calculated by a TPS
into secondary cancer risk. They did however state that Monte Carlo simulations
should be utilized for assessing the risk in low- and medium-dose regions because
of their higher accuracy. Most secondary cancers occur in low-dose areas [112,
113].
The developed tool makes the implementation of custom response models pos-
sible, both for TPS calculated doses and Monte Carlo doses. By some minor
modifications, the tool can evaluate the magnitude of doses inside delineated re-
gions/organs. These doses can (on a pixel-by-pixel basis) be further weighted,
converted, removed, and so forth, depending on what is desirable.
Scoring neutron doses
Neutrons can be a large contributer to the dose in the low-dose regions for particle
therapy [114, 115]. This is because neutrons do not carry any charge, and may
therefore deposit their dose far from the target volume [48]. To get a better
understanding of low-dose regions and associated neutron doses, it is necessary to
score the neutron associated doses inside the patient.
As mentioned, FLUKA is able to score numerous quantities not feasible for
a commercial treatment planning system. Therefore, by using the tool, clinical
treatment plans can be imported into FLUKA, where neutron doses can be scored
and further evaluated.
6.3 Suggestions for Further Work
Patient orientations that differ from head first - supine and head first - prone,
are not supported by any of the scripts. The reason for this was mainly because
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the scripts were first developed to be only able to handle gantry angles, and
therefore, due to time constraints, support for other orientations was not added.
However, a generalization of coordinate system transformations should be possible
to implement. The tool is furthermore not able to automatically handle rotations
of the treatment couch. However, for the CSI plan used in this project, the couch
was rotated. By manually changing the simulated gantry angle to correspond
to the specific couch angle, it was possible to recalculate the plans. Therefore,
automatic support for treatment table rotations could be added to the tool.
Automated removal of the treatment couch, and assigning vacuum to all regions
outside the patient, could be implemented to achieve better correspondence with
the treatment planning systems. This can be done by obtaining the positions of
all the pixels outside the delineated external contour of the patient, and setting
the Hounsfield units of these pixels equal to -1024.
Some minor modifications may be needed for dose recalculations of treatment
plans using other particles than protons, as this was not addressed in this project.
And further, to perform Monte Carlo recalculations with clinically acceptable
precision, the beam line, treatment head and other treatment room specifics should
be implemented into the Monte Carlo tool. In addition, proper calibration of




In this project, a Monte Carlo based treatment planning verification tool for par-
ticle therapy has been developed. The novel tool in this work reads relevant
treatment plan information from the DICOM format, and translates the data for
recalculations of dose within the FLUKA Monte Carlo code. Furthermore, scripts
for versatile comparisons of dose distributions from TPS and FLUKA were cre-
ated. A method for exporting the FLUKA recalculated doses to DICOM format
was also developed, which further enables import of Monte Carlo calculated plans
in commercial treatment planning systems.
In addition to recalculation of dose, the tool serves as a research framework
for studies including neutron doses and scoring of other secondary particles, LET
mapping, particle beam range verifications, clinically relevant endpoints such as
NTCP and secondary cancer visualization risk, and so forth.
The results in this thesis demonstrate the developed tool’s capability of recal-
culation of doses using Monte Carlo simulations. Furthermore, the results show
that detailed information of the beam line and beam configuration, and calibra-
tion with respect to a specific TPS or treatment machine, is essential in order to
achieve clinical precision in the recalculation process. Further work should focus





[1] R. W. Ruddon. Cancer Biology. 4th ed. Oxford University Press, 2007.
[2] N. S. Hosmane et al. Boron And Gadolinium Neutron Capture Therapy For
Cancer Treatment. 1st ed. World Scientific Publishing Company, 2012.
[3] J. Thariat et al. “Past, present, and future of radiotherapy for the benefit
of patients”. In: Nature Reviews Clinical Oncology 10.1 (2012), pp. 52–60.
[4] I. K. Larsen, ed. Cancer in Norway 2013 - Cancer incidence, mortality,
survival and prevalence in Norway (2015). Oslo: Cancer Registry of Nor-
way.
[5] Helse Vest, Helse Sør-Øst, Helse Midt-Norge, Helse Nord, Helsedirektoratet.
Planlegging av norsk senter for partikkelterapi. 2013.
[6] A. Van der Kogel and M. Joiner. Basic Clinical Radiobiology. 4th. A Hodder
Arnold Publication, 2009.
[7] H. Paganetti, ed. Proton Therapy Physics (Series in Medical Physics and
Biomedical Engineering). 1st ed. CRC Press, 2011.
[8] U. Amaldi and G. Kraft. “Radiotherapy with beams of carbon ions”. In:
Reports on Progress in Physics 68.8 (2005), pp. 1861–1882.
[9] M. Jermann. “Particle Therapy Statistics in 2014”. In: International Jour-
nal of Particle Therapy 2.1 (2015), pp. 50–54.
[10] O. H. Odland. “Status of Particle Therapy in Norway”. In: ENLIGHT
Highlights (2014), p. 17.
[11] M. Lederman. “The early history of radiotherapy: 1895–1939”. In: Inter-
national Journal of Radiation Oncology * Biology * Physics 7.5 (1981),
pp. 639–648.
[12] R. R. Wilson. “Radiological use of fast protons”. In: Radiology 47.5 (1946),
pp. 487–491.
[13] U. Linz, ed. Ion Beam Therapy: Fundamentals, Technology, Clinical Appli-
cations (Biological and Medical Physics, Biomedical Engineering). 2012th ed.
Springer, 2011.
[14] L. Hong et al. “A pencil beam algorithm for proton dose calculations”. In:
Physics in Medicine and Biology 41.8 (1996), pp. 1305–1330.
[15] J. Bauer et al. “Integration and evaluation of automated Monte Carlo sim-
ulations in the clinical practice of scanned proton and carbon ion beam
therapy”. In: Physics in Medicine and Biology 59.16 (2014), pp. 4635–4659.
[16] S. Yajnik. Proton Beam Therapy: How Protons are Revolutionizing Cancer
Treatment. 2013th ed. Springer, 2014.
83
84 BIBLIOGRAPHY
[17] K. S. Ytre-Hauge. “Measurements and Monte Carlo Simulations of Neutron
Doses from Radiation Therapy with Photons, Protons and Carbon Ions”.
PhD thesis. University of Bergen, 2013.
[18] S. Dhanesar et al. “SU-E-T-403: Intensity Modulated Proton Therapy Plans
with Multiple Fields for Prostate Cancer”. In: Medical Physics 40.6 (2013),
pp. 297–297.
[19] E. B. Podgorsak. Radiation Oncology Physics: A Handbook for Teachers
And Students. Intl Atomic Energy Agency, 2005.
[20] A. J. Lomax et al. “A treatment planning inter-comparison of proton and
intensity modulated photon radiotherapy”. In: Radiotherapy and Oncology:
Journal of the European Society for Therapeutic Radiology and Oncology
51.3 (1999), pp. 257–271.
[21] H. Paganetti. “Range uncertainties in proton therapy and the role of Monte
Carlo simulations”. In: Physics in Medicine and Biology 57.11 (2012), R99–
R117.
[22] C. H. Stokkev̊ag et al. “Risk of radiation-induced secondary rectal and blad-
der cancer following radiotherapy of prostate cancer”. In: Acta Oncologica
54.9 (2015), pp. 1317–1325.
[23] J. D. Boice et al. “Second cancers following radiation treatment for cervical
cancer. An international collaboration among cancer registries”. In: Journal
of the National Cancer Institute 74.5 (1985), pp. 955–975.
[24] D. J. Brenner et al. “Second malignancies in prostate carcinoma patients af-
ter radiotherapy compared with surgery”. In: Cancer 88.2 (2000), pp. 398–
406.
[25] C. H. Stokkev̊ag et al. “Estimated risk of radiation-induced cancer follow-
ing paediatric cranio-spinal irradiation with electron, photon and proton
therapy”. In: Acta Oncologica 53.8 (2014), pp. 1048–1057.
[26] D. L. Preston et al. “Solid cancer incidence in atomic bomb survivors:
1958-1998”. In: Radiation Research 168.1 (2007), pp. 1–64.
[27] A. Peeters et al. “How costly is particle therapy? Cost analysis of external
beam radiotherapy with carbon-ions, protons and photons”. In: Radiother-
apy and Oncology 95.1 (2010), pp. 45–53.
[28] M. Schwarz. “Treatment planning in proton therapy”. In: The European
Physical Journal Plus 126.7 (2011), pp. 1–10.
[29] M. Urie et al. “Degradation of the Bragg peak due to inhomogeneities”. In:
Physics in Medicine and Biology 31.1 (1986), pp. 1–15.
[30] P. Andreo. “On the clinical spatial resolution achievable with protons and
heavier charged particle radiotherapy beams”. In: Physics in Medicine and
Biology 54.11 (2009), N205–N215.
[31] Z. Li. “ICRU Report 78—Prescribing, Recording, and Reporting Proton-
Beam Therapy”. In: International Journal of Radiation Oncology * Biology
* Physics 73.5 (2009), p. 1602.
BIBLIOGRAPHY 85
[32] H. Jiang and H. Paganetti. “Adaptation of GEANT4 to Monte Carlo dose
calculations based on CT data”. In: Medical Physics 31.10 (2004), pp. 2811–
2818.
[33] A. Tourovsky et al. “Monte Carlo dose calculations for spot scanned proton
therapy”. In: Physics in Medicine and Biology 50.5 (2005), pp. 971–981.
[34] B. Juste et al. “Radiotherapy treatment planning based on Monte Carlo
techniques”. In: Nuclear Instruments and Methods in Physics Research Sec-
tion A: Accelerators, Spectrometers, Detectors and Associated Equipment.
Frontiers in radiation physics and applications:Proceedings of the 11th In-
ternational Symposium on Radiation Physics 619.1–3 (2010), pp. 252–257.
[35] H. Paganetti et al. “Clinical implementation of full Monte Carlo dose calcu-
lation in proton beam therapy”. In: Physics in Medicine and Biology 53.17
(2008), p. 4825.
[36] A. Mesbahi, D. I. Thwaites, and A. J. Reilly. “Experimental and Monte
Carlo evaluation of Eclipse treatment planning system for lung dose cal-
culations”. In: Reports of Practical Oncology & Radiotherapy 11.3 (2006),
pp. 123–133.
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[74] D. Schulz-Ertner, O. Jäkel, and W. Schlegel. “Radiation Therapy With
Charged Particles”. In: Seminars in Radiation Oncology 16.4 (2006), pp. 249–
259.
[75] J. M. Schippers. “Beam delivery systems for particle radiation therapy:
current status and recent developments”. In: Reviews of Accelerator Science
and Technology 2.01 (2009), pp. 179–200.
[76] M. Engelsman, M. Schwarz, and L. Dong. “Physics Controversies in Proton
Therapy”. In: Seminars in Radiation Oncology 23.2 (2013), pp. 88–96.
[77] C. Grupen and I. Buvat, eds. Handbook of Particle Detection and Imaging.
2012th ed. Springer, 2011.
88 BIBLIOGRAPHY
[78] G. O. Sawakuchi et al. “Density heterogeneities and the influence of mul-
tiple Coulomb and nuclear scatterings on the Bragg peak distal edge of
proton therapy beams”. In: Physics in Medicine and Biology 53.17 (2008),
pp. 4605–4619.
[79] N. Kanematsu et al. “A CT calibration method based on the polybinary
tissue model for radiotherapy treatment planning”. In: Physics in medicine
and biology 48.8 (2003), p. 1053.
[80] V. Vlachoudis. “FLAIR: a powerful but user friendly graphical interface for
FLUKA”. In: Proc. Int. Conf. on Mathematics, Computational Methods &
Reactor Physics (M&C 2009), Saratoga Springs, New York. 2009.
[81] W. Schneider, T. Bortfeld, and W. Schlegel. “Correlation between CT num-
bers and tissue parameters needed for Monte Carlo simulations of clinical
dose distributions”. In: Physics in Medicine and Biology 45.2 (2000), p. 459.
[82] K. Parodi et al. “Clinical CT-based calculations of dose and positron emit-
ter distributions in proton therapy using the FLUKA Monte Carlo code”.
In: Physics in Medicine and Biology 52.12 (2007), pp. 3369–3387.
[83] A. Ferrari et al. FLUKA: a multi-particle transport code (Manual). Stanford
Linear Accelerator Center (SLAC). 2014.
[84] National Electrical Manufacturers Association (NEMA). DICOM PS3.3
2014a - Information Object Definitions. NEMA. DICOM Standards Com-
mittee, 2014.
[85] IEC TC/SC 62C. IEC 61217 Ed. 1.1 b:2002, Radiotherapy equipment - Co-
ordinates, movements and scales. Multiple. Distributed through American
National Standards Institute (ANSI), 2007.
[86] O. Ratib. “OSIRIX: An Open Source Platform for Advanced Multimodality
Medical Imaging”. In: 2006 ITI 4th International Conference on Informa-
tion Communications Technology. 2006, pp. 1–2.
[87] G. van Rossum and the Python development team. The Python Language
Reference. Reference Manual. Version 2.7.11. Python Software Foundation,
2016.
[88] D. Mason. “SU-E-T-33: Pydicom: An Open Source DICOM Library”. In:
Medical Physics 38.6 (2011), pp. 3493–3493.
[89] S. van der Walt, S. C. Colbert, and G. Varoquaux. “The NumPy Array: A
Structure for Efficient Numerical Computation”. In: Computing in Science
& Engineering 13.2 (2011), pp. 22–30.
[90] J. D. Hunter. “Matplotlib: A 2D Graphics Environment”. In: Computing
in Science & Engineering 9.3 (2007), pp. 90–95.
[91] A. Panfili. “Development of a Monte Carlo tool to verify Treatment Plan-
ning in proton therapy at CNAO”. Thesis. University of Milan, 2011.
BIBLIOGRAPHY 89
[92] N. Bassler and I. Kantemiris. “Comparison of optimized single and mul-
tifield irradiation plans of antiproton, proton and carbon ion beams”. In:
Radiotherapy and oncology : journal of the European Society for Therapeu-
tic Radiology and Oncology 95.1 (2010), pp. 87–93.
[93] R. Malyapa et al. “Evaluation of Robustness to Setup and Range Uncer-
tainties for Head and Neck Patients Treated With Pencil Beam Scanning
Proton Therapy”. In: International Journal of Radiation Oncology * Biol-
ogy * Physics 95.1 (2016), pp. 154–162.
[94] Dicomutils. url: https://github.com/raysearchlabs/dicomutils.git
(visited on 05/05/2016).
[95] R. J. Packer et al. “Survival and secondary tumors in children with medul-
loblastoma receiving radiotherapy and adjuvant chemotherapy: results of
Children’s Oncology Group trial A9961”. In: Neuro-Oncology 15.1 (2013),
pp. 97–103.
[96] T. Bortfeld. “An analytical approximation of the Bragg curve for thera-
peutic proton beams”. In: Medical Physics 24.12 (1997), p. 2024.
[97] W. C. Hsi et al. “Energy spectrum control for modulated proton beams”. In:
Medical Physics 36.6 (June 2009), pp. 2297–2308. (Visited on 05/31/2016).
[98] H. Paganetti. “Dose to water versus dose to medium in proton beam ther-
apy”. In: Physics in Medicine and Biology 54.14 (2009), pp. 4399–4421.
[99] A. C. Guyton and J. E. Hall. Textbook of Medical Physiology. 11th ed.
Saunders, 2005.
[100] R. M. Howell et al. “Accuracy of out-of-field dose calculations by a com-
mercial treatment planning system”. In: Physics in Medicine and Biology
55.23 (2010), pp. 6999–7008.
[101] K. Parodi et al. “Monte Carlo simulations to support start-up and treat-
ment planning of scanned proton and carbon ion therapy at a synchrotron-
based facility”. In: Physics in Medicine and Biology 57.12 (2012), pp. 3759–
3784.
[102] T. V. M. Lima et al. “Monte Carlo Calculations Supporting Patient Plan
Verification in Proton Therapy”. In: Frontiers in Oncology 6 (2016).
[103] R. Jeraj and P. Keall. “The effect of statistical uncertainty on inverse
treatment planning based on Monte Carlo dose calculation”. In: Physics
in Medicine and Biology 45.12 (2000), p. 3601.
[104] J. V. Siebers et al. “Converting absorbed dose to medium to absorbed dose
to water for Monte Carlo based photon beam dose calculations”. In: Physics
in Medicine and Biology 45.4 (2000), p. 983.
[105] H. Jiang, J. Seco, and H. Paganetti. “Effects of Hounsfield number con-
version on CT based proton Monte Carlo dose calculations”. In: Medical
physics 34.4 (2007), pp. 1439–1449.
90 BIBLIOGRAPHY
[106] D. A. Granville and G. O. Sawakuchi. “Comparison of linear energy trans-
fer scoring techniques in Monte Carlo simulations of proton beams”. In:
Physics in Medicine and Biology 60.14 (2015), N283.
[107] C. Grassberger et al. “Variations in linear energy transfer within clinical
proton therapy fields and the potential for biological treatment planning”.
In: International Journal of Radiation Oncology * Biology * Physics 80.5
(2011), pp. 1559–1566.
[108] J. B. Robertson et al. “Radiobiological studies of a high-energy modulated
proton beam utilizing cultured mammalian cells”. In: Cancer 35.6 (1975),
pp. 1664–1677.
[109] H. Suit et al. “Proton vs carbon ion beams in the definitive radiation treat-
ment of cancer patients”. In: Radiotherapy and Oncology 95.1 (2010), pp. 3–
22.
[110] G. Giovannini et al. “Variable RBE in proton therapy: comparison of dif-
ferent model predictions and their influence on clinical-like scenarios”. In:
Radiation Oncology 11 (2016), p. 68.
[111] R. Zhang, D. Mirkovic, and W. D. Newhauser. “Visualization of risk of
radiogenic second cancer in the organs and tissues of the human body”. In:
Radiation Oncology 10.1 (2015).
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